Cherry Picking with Synthetic Controls by Ferman, Bruno et al.
MPRA
Munich Personal RePEc Archive
Cherry Picking with Synthetic Controls
Bruno Ferman and Cristine Pinto and Vitor Possebom
Sao Paulo School of Economics - FGV, Sao Paulo School of
Economics - FGV, Yale
24 August 2017
Online at https://mpra.ub.uni-muenchen.de/80970/
MPRA Paper No. 80970, posted 25 August 2017 16:21 UTC
Cherry Picking with Synthetic Controls∗
Bruno Ferman† Cristine Pinto‡ Vitor Possebom§
Sao Paulo School of Economics - FGV Sao Paulo School of Economics - FGV Yale University
First Draft: June 2016
This Draft: August 2017
Please click here for the most recent version
Abstract
We evaluate whether a lack of guidance on how to choose the matching variables used in the
Synthetic Control (SC) estimator creates specification-searching opportunities. We first provide
theoretical results showing that specification-searching opportunities would be asymptotically ir-
relevant when the number of pre-treatment periods goes to infinity when we restrict to a subset of
SC specifications. However, based on Monte Carlo simulations and simulations with real datasets,
we show significant room for specification searching when the number of pre-treatment periods is
finite and when other SC specifications commonly used in SC applications are also considered. This
undermines one of the potential advantages of the method, which is providing a transparent way of
choosing comparison units and, therefore, being less susceptible to specification searching than al-
ternative methods. To address this problem, we provide recommendations to limit the possibilities
for specification searching in the SC method. Finally, we analyze the possibilities for specification
searching and our recommendations in two empirical applications.
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1 Introduction
The synthetic control (SC) method has been recently proposed in a series of seminal papers
by Abadie & Gardeazabal (2003), Abadie et al. (2010), and Abadie et al. (2015) as an alternative
method to estimate treatment effects in comparative case studies. Despite being relatively new,
this method has been used in a wide range of applications, including the evaluation of the impact
of terrorism, civil wars and political risk, natural resources and disasters, international finance,
education and research policy, health policy, economic and trade liberalization, political reforms,
labor, taxation, crime, social connections, and local development.1 Athey & Imbens (2017) describe
the SC method as arguably the most important innovation in the evaluation literature in the last
fifteen years.
Abadie et al. (2010) and Abadie et al. (2015) describe many advantages of the SC estimator
over techniques traditionally used in comparative studies. Among them, one important feature
of the SC method is that it provides a transparent way to choose comparison units. In the SC
method, a data-driven process is used to choose the weights that will build the weighted-average
of the controls’ outcomes that will represent the counterfactual for the treated unit. Also, since
the estimation of the SC weights does not require access to post-intervention outcomes, researchers
could decide on the study design without knowing how those decisions would affect the conclusions
of their studies. Taken together, these features potentially make the SC method less susceptible to
specification searching relative to alternative methods for comparative case studies. This could be
an important advantage of the SC method given the growing debate about transparency in social
science research (Miguel et al. (2014)).2
An important limitation of the SC method, however, is that it does not provide clear guidance
1SC has been used in the evaluation of the impact of terrorism, civil wars and political risk (Abadie & Gardeazabal
(2003), Bove et al. (2014), Li (2012), Montalvo (2011), Yu & Wang (2013)), natural resources and disasters (Barone
& Mocetti (2014), Cavallo et al. (2013), Coffman & Noy (2011), DuPont & Noy (2012), Mideksa (2013), Sills et al.
(2015), Smith (2015)), international finance (Jinjarak et al. (2013), Sanso-Navarro (2011)), education and research
policy (Belot & Vandenberghe (2014), Chan et al. (2014), Hinrichs (2012)), health policy (Bauhoff (2014), Kreif
et al. (2015)), economic and trade liberalization (Billmeier & Nannicini (2013), Gathani et al. (2013), Hosny (2012)),
political reforms (Billmeier & Nannicini (2009), Carrasco et al. (2014), Dhungana (2011) Ribeiro et al. (2013)), labor
(Bohn et al. (2014), Calderon (2014)), taxation (Kleven et al. (2013), de Souza (2014)), crime (Pinotti (2012b),
Pinotti (2012a),Saunders et al. (2014)), social connections (Acemoglu et al. (2013)), and local development (Ando
(2015), Gobillon & Magnac (2016), Kirkpatrick & Bennear (2014), Liu (2015), Possebom (2017), Severnini (2014)).
2 See Christensen & Miguel (2016) for an extensive literature review on research transparency and reproducibility
both in economics and other fields.
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on the choice of predictor variables that should be used to estimate the SC weights.3 Although
Abadie et al. (2010) define vectors of linear combinations of pre-intervention outcomes that could be
used as predictors, there is no specific recommendation about which variables should be used. Such
lack of guidance on how to choose the predictors when implementing the synthetic control method
translates into a wide variety of different specifications in empirical applications of this method.
For example, some applied papers use all pre-treatment outcome lags as economic predictors, other
papers select a subset of the pre-treatment outcome lags as economic predictors, while other papers
use the mean of all pre-treatment outcome lags and other covariates as economic predictors.4 If
different specifications result in widely different choices of the SC unit, then a researcher would
have relevant opportunities to select “statistically significant” specifications even when there is no
effect.5 Since a researcher would usually not be able to commit to a particular specification before
knowing how these decisions would affect the conclusion of her study, this flexibility may undermine
one of the main advantages of the SC method.6
In this paper, we evaluate the extent to which this variety of options in the synthetic control
method creates opportunities for specification searching considering only one particular step of
the method: the choice of predictors used in the estimation of the SC weights.7 We first provide
conditions under which the placebo test suggested in Abadie et al. (2010) will asymptotically lead
3To the best of our knowledge, Dube & Zipperer (2015) and Kaul et al. (2015) are the only other authors to point
out that there is little explicit guidance in the SC literature to determine the choice of predictors. However, they
do not explore the implications of such lack of specific guidance on the possibilities for specification searching in SC
applications.
4For example, Abadie & Gardeazabal (2003), Abadie et al. (2015) and Kleven et al. (2013) use the mean of all
pre-treatment outcome values and other covariates as predictors; Billmeier & Nannicini (2013), Bohn et al. (2014),
Gobillon & Magnac (2016), Hinrichs (2012) use all the pre-treatment outcome values; Smith (2015) selects 4 out of
10 pre-treatment periods; Abadie et al. (2010) select 3 out of 19 pre-treatment periods; and Montalvo (2011) uses
only the last two pre-treatment outcome values.
5We consider for inference the placebo test suggested in Abadie et al. (2010). Although this is not a formal
randomization test if treatment is not randomly assigned, we focus on this test because it is the most commonly used
test in SC application. We can think of this test as the probability of having a test statistic on the top 5% of the
distribution of test statistics in the placebo runs. In practice, this is how applied researchers evaluate whether the
SC estimator is significant in their applications. Moreover, the randomization inference assumptions are valid in the
data generating processes in our simulations. Therefore, the placebo test is statistically valid in our simulations. See
?, Ferman & Pinto (2017) and Hahn & Shi (2016) for details on the statistical properties of this test.
6Olken (2015) and Coffman & Niederle (2015) evaluate the use of pre-analysis plans in social sciences. For ran-
domized control trials (RCT), the American Economic Association (AEA) launched a site to register experimental
designs. However, there is no site where one would be able to register a prospective synthetic control study. More-
over, in many synthetic control applications both pre- and post-intervention information would be available to the
researcher before the possibility of registering the study. In this case, it would be unfeasible to commit to a particular
specification.
7There may be other dimensions in the implementation of the SC method that provide discretionary choices for
the researcher. For example, Klo¨bner et al. (2016) show that different SC estimators are obtained depending on the
software used or on how the dataset is sorted.
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to the same conclusion regardless of the SC specification when the number of pre-treatment periods
(T0) goes to infinity, as long as we restrict to specifications such that the number of pre-treatment
outcome lags used as predictors goes to infinity with T0.
8 Note, however, that many SC applications
does not have a large number of pre-treatment periods to justify large-T0 asymptotics, as argued
in Doudchenko & Imbens (2016), which may still leave room to specification searching even if we
restrict to this class of SC specifications. Moreover, there are common SC specifications that do not
satisfy the condition on the number of pre-treatment periods used as predictors going to infinity,
which might lead to specification-searching opportunities even when the number of pre-treatment
periods is large.
We then evaluate the extent to which specification searching may be a problem in SC applica-
tions using Monte Carlo (MC) simulations and placebo simulations with the Current Population
Survey (CPS) in which we calculate the probability that a researcher would find at least one specifi-
cation that would lead him to reject the null at 5%.9 If different SC specifications lead to similar SC
estimators, then the probability of rejecting the null in at least one specification would be close to
5%. If, however, different SC specifications lead to wildly different estimates, then the probability
that a researcher would be able to find a specification that rejects the null at 5% can be much
higher than 5%, implying significant room for specification searching. We consider six different
specifications commonly used in SC applications: (1) the mean of all pre-treatment outcome val-
ues, (2) all pre-treatment outcome values, (3) the first half of the pre-treatment outcome values,
(4) the first three quarters of the pre-treatment outcome values, (5) odd pre-treatment outcome
values, and (6) even pre-treatment outcome values.10
We find that the probability of detecting a false positive in at least one specification can be as
8This happens because all such specification will be asymptotically equivalent when the number of pre-treatment
periods goes to infinity.
9We consider for inference the placebo test suggested in Abadie et al. (2010). Although this is not a formal
randomization test if treatment is not randomly assigned, we focus on this test because it is the most commonly
used test in SC application. Therefore, our simulation exercises can be seen as the probability that a researcher
applying the SC method would find a test statistic that is in the top 5% of the distribution of test statistics in
the placebo runs. In practice, this is how applied researchers evaluate whether the SC estimator is significant in
their applications. Moreover, the randomization inference assumptions are valid in the data generating processes in
our simulations. Therefore, the placebo test is statistically valid in our simulations. See Firpo & Possebom (2016),
Ferman & Pinto (2017) and Hahn & Shi (2016) for details on the statistical properties of this test.
10In order to simplify the presentation of our results, we do not consider in our simulations the use of time-invariant
covariates, as is commonly used in specifications that rely on the pre-treatment outcome mean. In Appendix B we show
that our results remain valid if we consider specifications that use time-invariant covariates as economic predictors
in addition to functions of the pre-treatment outcomes. Note also that these six specifications do not exhaust all
specification options that have been considered in SC applications.
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high as 13% when there are 12 pre-treatment periods (22% if we consider a 10% significance test).
The possibilities for specification searching remain high even when the number of pre-treatment
periods is large. With 400 pre-treatment periods, we still find a probability of around 11% that
at least one specification is significant at 5% (21% if we consider a 10% significance test). These
results suggest that, even with a large number of pre-treatment periods, different specifications
can lead to significantly different synthetic control units, generating substantial opportunities for
specification searching. This is true both in data generating processes with stationary and non-
stationary common factors. We also find similar results in placebo simulations using the CPS.
Importantly, we still find that the probability of rejecting the null in at least one specification
can be significantly higher than the nominal test size even when we restrict the set of choices to
specifications with a good pre-treatment fit.11
Given our theoretical results, it is expected that the significant specification-searching possibil-
ities with a large T0 are driven by specifications that do not increase the number of pre-treatment
lags used as predictors when the number of pre-treatment periods goes to infinity. Indeed, we find
that excluding the specification that uses the pre-treatment average of the outcome as predictor
from the set of options strongly attenuates the specification-searching problem when T0 is large,
although we still find significant room for specification searching when the T0 is not so large. Note
that the data-generating process (DGP) in our MC simulations also provides a way to measure the
extent to which different specifications assign positive weight to control units that should not be
considered in the synthetic control unit. Consistent with the intuition that specifications that use
more pre-treatment outcome lags as predictors would better control for unobserved confounders,
we find that the specifications that limit the number of pre-treatment outcome lags misallocate
substantially more weights, suggesting that such specifications should not be considered in SC
applications.
11There are at least two possible explanations for still finding over-rejection even when we condition on specifications
with a good pre-treatment fit. First, in many SC applications, including those in Abadie & Gardeazabal (2003),
Abadie et al. (2010), and Abadie et al. (2015), the outcome variable is non-stationary. In this case, most SC
specifications will provide a good pre-treatment fit, as it will provide a good approximation to the non-stationary
trend, as shown in Ferman & Pinto (2016). Our results suggest that, in this scenario, different SC specifications
can still yield substantially different estimators even if most specifications provide a good approximation to the non-
stationary trend. Second, as shown in Ferman & Pinto (2017), the SC permutation test can lead to over-rejection if
we consider the SC estimator conditional on a good pre-treatment fit. This explains why we may still have significant
over-rejection even when the researcher has only a few (or even just one) specifications with a good pre-intervention
fit to choose from.
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It is important to note that our results by no means imply that researchers that have imple-
mented the SC method did engage in specification searching. Given that this is a relatively new
method, there would not be enough papers to formally test for specification searching.12 However,
given the mounting evidence that there is a high return for reporting “significant” results and that
scientists tend to engage in p-hacking, our findings raise important concerns about the synthetic
control method.13 Also, while we find room for specification searching in the SC method, it does
not imply that this problem is more relevant for the SC method when compared to alternatives
methods.14 The main conclusion of our paper is that, despite providing a data-driven method
to construct the counterfactual unit, the SC method does not completely solve the specification-
searching problem due to a lack of consensus on how the SC weights should be estimated.
If there were a consensus on how the SC specification should be selected, then the risk of p-
hacking (at least in this dimension) would be limited. Our results suggest that restricting the
set of options for researchers can strongly attenuate this problem, particularly if we restrict to
specifications that use many pre-treatment outcome lags as predictors. Another possible solution
would be to require researchers applying the SC method to report results for different specifications.
However, it is important to note that testing all the possible SC specifications separately would
not provide a valid hypothesis test since there would not be a defined decision rule (see White
(2000)). One alternative is to consider a test statistic for the permutation test that combines the
test statistics for all individual specifications, as suggested in Imbens & Rubin (2015). Finally,
another alternative would be to have a data-driven rule to determine which specification should be
used. As an example, Dube & Zipperer (2015) propose a mean squared prediction error (MSPE)
criterion based on the estimated post-treatment effects in placebo estimations whose minimizer
could be the focus of an analysis that uses the synthetic control method.
12Brodeur et al. (2016) analyzes 641 articles (providing more than 50,000 tests) published in the American Economic
Review, the Journal of Political Economy, and the Quarterly Journal of Economics. They identify a residual in the
distribution of tests that cannot be explained solely by journals favoring rejection of the null hypothesis. Simonsohn
et al. (2014) suggest the use of the p-curve as a way to distinguish between selective reporting findings and true
effects. One of the requirements to the inference from p-curve to be valid is that we have a great pool of studies from
which we can select studies and p-values that test similar hypothesis. Given that the synthetic control estimator is
a relatively recent method, there would not be enough published papers that used this method even if we consider
a wide range of journals. Therefore, it would be unfeasible to replicate these methodologies for synthetic control
applications.
13See Rosenthal (1979), Lovell (1983), De Long & Lang (1992), Simmons et al. (2011), Simonsohn et al. (2014),
and Brodeur et al. (2016).
14For example, Gardeazabal & Vega-Bayo (2016) compare the synthetic control method with a panel data approach
developed in Hsiao et al. (2012), and conclude that the SC estimator is more robust to changes in the donor pool.
6
Finally, we also consider the possibilities for specification searching and the implementability
of the above recommendations in two empirical applications, based on Smith (2015) and Abadie
et al. (2010). In our empirical examples, we analyze three cases: one whose conclusion is robust
to specification searching, one where different specifications can reach either significant and non-
significant results (clearly showing the potential for specification searching in the synthetic control
framework), and one where all results are significant, but at different significance levels. Moreover,
after applying our recommendations, we show that one can reach a clear conclusion about the
significance of the results in all three examples.
The remainder of this paper proceeds as follows. In Section 2, we provide a brief overview of
the SC estimation, and then we provide conditions under which the SC estimators using different
specifications will be asymptotically equivalent when the number of pre-treatment periods goes
to infinity, if we restrict to a particular set of SC specifications. Then, we provide Monte Carlo
simulations in Section 3 and simulations with real data in Section 4. We present our main recom-
mendations in Section 5, and we discuss three empirical examples in Section 6. We conclude in
Section 7.
2 Synthetic Control Method and Specification Searching
Abadie & Gardeazabal (2003), Abadie et al. (2010) and Abadie et al. (2015) have recently
developed the Synthetic Control Method in order to address counterfactual questions involving only
one treated unit and a few control units. Intuitively, this method estimates the potential outcome
of the treated unit if there were no treatment by constructing a weighted average of control units
that is as similar as possible to the treated unit regarding the pre-treatment outcome variables and
covariates. For this reason, this weighted average of control units is known as the synthetic control
unit and treatment effects can be flexibly estimated for each post-treatment period. Below, we
follow Abadie et al. (2010), explaining their estimator.
Suppose that we observe data for (J + 1) ∈ N units during T ∈ N time periods. Additionally,
assume that there is a treatment that affects only unit 1 from period T0 + 1 to period T uninter-
ruptedly, where T0 ∈ (1, T )∩N. Let the scalar Y 0j,t be the potential outcome that would be observed
for unit j in period t if there were no treatment for j ∈ {1, ..., J + 1} and t ∈ {1, ..., T}. Let the
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scalar Y 1j,t be the potential outcome that would be observed for unit j in period t if unit j received
the treatment from period T0 + 1 to T . Define:
αj,t := Y
1
j,t − Y 0j,t (1)
as the treatment effect for unit j in period t and Dj,t as a dummy variable that assumes value 1 if
unit j is treated in period t and value 0 otherwise. With this notation, we have that the observed
outcome for unit j in period t is given by
Yj,t := Y
0
j,t (1−Dj,t) + Y 1j,tDj,t.
Since only the first unit receives the treatment from period T0 + 1 to T , we have that:
Dj,t :=
 1 if j = 1 and t > T00 otherwise.
We aim to identify (α1,T0+1, ..., α1,T ). Since Y
1
1,t is observable for t > T0, equation (1) guarantees
that we only need to estimate the counterfactual Y 01,t to accomplish this goal.
Let Yj := [Yj,1...Yj,T0 ]
′ be the vector of observed outcomes for unit j ∈ {1, ..., J + 1} in the
pre-treatment period and Xj a (F ×1)-vector of predictors of Yj. Those predictors can be not only
covariates that explain the outcome variable, but also linear combinations of the variables in Yj.
15
Let also Y0 = [Y2...YJ+1] be a (T0 × J)-matrix and X0 = [X2...XJ+1] be a (F × J)-matrix.
Given the choice of predictors in matrix Xj, the idea of the SC method is to construct the
counterfactual for the treated unit using a weighted average of the control units:
Ŷ 01,t :=
J+1∑
j=2
ŵjYj,t (2)
The weights Ŵ = [ŵ2...ŵj+1]
′ := Ŵ(V̂) ∈ RJ are given by the solution to a nested minimization
problem:
15For example, if the outcome variable is a country’s per capita GDP and T0 = 12, Xj may contain the investment
rate, some measures of human capital and institutional quality, population, and the average per capita GDP from 1
to 4, from 5 to 8 and from 9 to 12.
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Ŵ(V) := arg min
W∈W
(X1 −X0W)′V(X1 −X0W) (3)
where W :=
{
W = [w2...wJ+1]
′ ∈ RJ : wj ≥ 0 for each j ∈ {2, ..., J + 1} and
∑J+1
j=2 wj = 1
}
and
V is a diagonal positive semidefinite matrix of dimension (F×F ) whose trace equals one. Moreover,
V̂ := arg min
V∈V
(Y1 −Y0Ŵ(V))′(Y1 −Y0Ŵ(V)) (4)
where V is the set of diagonal positive semidefinite matrix of dimension (F ×F ) whose trace equals
one.
Finally, we define the Synthetic Control Estimator of α1,t (or the estimated gap) as
α̂1,t := Y1,t − Ŷ N1,t (5)
for each t ∈ {1, ..., T}.
Intuitively, Ŵ is a weighting vector that measures the relative importance of each unit in the
synthetic control of unit 1 and V̂ measures the relative importance of each one of the F predictors.
Abadie et al. (2010) discuss alternative ways to choose the matrix V̂. We focus our attention on
the most common method of choosing V̂, which involves solving the nested minimization problem
given by equations (3) and (4).
Even though a crucial part in the implementation of the SC method is the choice of economic
predictors, there is little guidance about which variables should be included in matrix Xj. This
lack of guidance can create an opportunity for the researcher to look for specifications that yield
“better” results by including or excluding some pre-treatment outcome values from its specification.
This risk is even greater when we consider that there is no consensus about which functions of the
outcome values should be included in Xj: Abadie & Gardeazabal (2003), Abadie et al. (2015) and
Kleven et al. (2013) use the mean of all pre-treatment outcome values and additional covariates;
Smith (2015) uses Yj,T0 , Yj,T0−2, Yj,T0−4 and Yj,T0−6; Abadie et al. (2010) picks Yj,T0 , Yj,T0−8 and
Yj,T0−13; Billmeier & Nannicini (2013), Bohn et al. (2014), Gobillon & Magnac (2016), Hinrichs
(2012) use all pre-treatment outcome values; and Montalvo (2011) uses only the last two pre-
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treatment outcome values.16
A key question, therefore, is whether different specifications may lead to substantially different
SC estimators. We consider the asymptotic behavior of different SC specifications when T0 →∞.
We define a specification s by the set of predictors Xj(s, T0) that are used when there are T0 pre-
treatment periods. Let I(s, T0) be the set of pre-treatment periods t such that Yj,t is included as
a predictor when there are T0 pre-treatment periods, and let L(s, T0) = #I(s, T0).17 Let y0−j,t be
the J × 1 vector of potential outcomes for all units except unit j at time t. We consider a sufficient
assumption to guarantee that a broad set of SC specifications will be asymptotically equivalent
when T0 →∞.
Assumption 1 For any sequence of integers {tk}k∈N with tk > tk−1, and for any j ∈ {1, ..., J+1},
we have that:
supW∈W
∣∣∣∣∣ 1K
K∑
k=1
(
Y 0j,tk − y0−j,tk
′
W
)2 −Qj(W)
∣∣∣∣∣ p→ 0 when K →∞ (6)
where Qj(W) is a continuous and strictly convex function.
Note that assumption 1 implies that pre-treatment averages of the second moments of every
subsequence of (Y 01,t, ..., Y
0
J+1,t) converge to the same value. We show in Appendix A that this
assumption is satisfied if, for example, we assume that {y0ty0t ′}T0t=1 is weakly stationarity, each
element of {y0ty0t ′} has absolutely summable covariances, and E
[
y0ty
0
t
′]
is non-singular, where
y0t = (Y
0
1,t, ..., Y
0
J+1,t)
′.
Given these assumptions, we have the following results (all proofs are presented in Appendix
A):
Proposition 1 Let Ŵ(s, T0) be the SC weights using specification s when there are T0 pre-
intervention periods. If L(s, T0) → ∞ when T0 → ∞, then, under assumption 1, Ŵ(s, T0) p→
W¯ = argminW∈WQ0(W).
16By no means we imply that those authors have engaged in specification searching. We have only listed them as
prominent examples of different choices regarding predictor variables.
17For example, let a specification s be such that R covariates and the first half of the pre-treatment outcome lags
are used as predictors. Then I(s, T0) = {1, 2, ..., T02 } and L(s, T0) = T02 . Note that, in this case, the dimension of Xj
would be R+ T0
2
.
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Corollary 2 Let αˆ1t(s, T0) and αˆ1t(s
′, T0) be two SC estimators for the treatment effect at time
t > T0 using specifications s and s
′ such that L(s, T0) → ∞ and L(s′, T0) → ∞ when T0 → ∞.
Then, under assumption 1 |αˆ1t(s, T0)− αˆ1t(s′, T0)| = op(1).
Therefore, while different SC specifications may generate different SC estimates, our result
from Proposition 1 and Corollary 2 show that, under some conditions, different specifications will
lead to asymptotically equivalent SC estimators, as long as the number of pre-treatment lags used
as predictors goes to infinity with T0. Note, however, that our results do not guarantee that
different SC specifications would lead to similar SC estimates when T0 is finite. Moreover, there
are common specifications used in SC applications that do not satisfy the condition on the number
of pre-treatment lags used as economic predictors going to infinity with T0. For example, many
authors consider the use of the mean of all pre-treatment outcome values in addition to other
covariates as economic predictors, while other authors consider the use of only a few pre-treatment
outcome lags as economic predictors. These alternative specifications would generally lead to SC
weights that will not converge to W¯, so there may still be significant variation in the SC estimates
even when T0 is large.
Note that our results are valid irrespectively of whether the SC estimator is unbiased, as we are
only comparing the asymptotic behavior of the SC estimator under different specifications. For a
thorough analysis on the asymptotic bias of the SC estimator when T0 →∞, see Ferman & Pinto
(2016). In our simulations in Sections 3 and 4, the condition in which the SC estimator is unbiased
are satisfied. Also, note that our results are related to the results from Kaul et al. (2015), who show
that covariates would become irrelevant in the minimization problem 3 if all pre-treatment lags are
included as predictors. Since our result from Proposition 1 holds whether or not we include other
covariates as predictors, this implies that covariates would also become asymptotically irrelevant
in the minimization problem 3 whenever we consider specifications such that L(s, T0) → ∞ when
T0 → ∞, even if we do not include all pre-treatment outcome lags. Note, however, that this does
not necessarily imply that the SC weights will not attempt to match the covariates of the treated
unit nor that the SC estimator will be asymptotically biased, as explained in Botosaru & Ferman
(2017).
Conditional on a given SC specification, Abadie et al. (2015) propose an inference procedure
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that consists in a straightforward placebo test. They permute which unit is assumed to be treated
and estimate, for each j ∈ {2, ..., J + 1} and t ∈ {1, ..., T}, α̂j,t as described above. Then, they
compute the test statistic
RMSPEj :=
∑T
t=T0+1
(
Yj,t − Ŷ Nj,t
)2/(T − T0)∑T0
t=1
(
Yj,t − Ŷ Nj,t
)2/T0
where the acronym RMSPE stands for ratio of the mean squared prediction errors. Moreover, they
propose to calculate a p-value
p :=
∑J+1
j=1 1 [RMSPEj ≥ RMSPE1]
J + 1
, (7)
where 1[] is the indicator function of event , and reject the null hypothesis of no effect if p is less
than some pre-specified significance level, such as the traditional value of 0.05. Abadie et al. (2010)
recognize that the randomization inference assumptions are very restrictive for the SC set-up, as
treatment is not, in general, randomly assigned.18 In the absence of random assignment, they
interpret the p-value as the probability of obtaining an estimate value for the test statistics at least
as large as the value obtained using the treated case as if the intervention was randomly assigned
among the data. Although the p-value from this placebo test lacks a clear statistical interpretation,
this test is commonly used in SC application. Therefore, our simulation exercises can be seen as
the probability that a researcher applying the SC method would find a test statistic that is in the
top 5% of the distribution of test statistics in the placebo runs, which is how researchers applying
the SC method usually assess whether their estimates are significant. Moreover, note that, in our
simulations, the placebo test considering a single SC specification would have a rejection rate under
the null of 5% by construction.
As a corollary from Proposition 1, we show that the ranking of RMSPEj will remain asymp-
totically invariant to changes in the SC specification when T0 → ∞ as long as we consider only
specifications such that the number of pre-treatment outcome lags goes to infinity with T0.
Corollary 3 Under assumption 1 and assuming that Yjt is continuous, the ordering of {RMSPE1, ...,
18Firpo & Possebom (2016) discuss a sensitivity mechanism analysis for this test, while Ferman & Pinto (2017)
analyze the statistical properties of this placebo test when treatment is not randomly assigned. Hahn & Shi (2016)
also consider the properties of placebo test in the SC setting. For our purposes in this paper, we consider Abadie
et al. (2010) interpretation of the placebo test p-value.
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RMSPEJ+1} is asymptotically invariant to SC specifications such that L(s, T0)→∞ with T0 and
T − T0 is finite.
The result from corollary 3 shows that, if we restrain to SC specifications such that number of
pre-treatment outcome lags goes to infinity with T0, then the possibilities for specification searching
would be limited, as a test based on different SC specifications would lead to the same conclusion
with probability approaching to one when T0 → ∞. It is important to emphasize, however, that
we may still have room for specification searching if T0 is finite. Moreover, this result is not valid if
we consider alternative SC specifications such that the number of pre-treatment outcome lags used
as economic predictors remain fixed when T0 →∞.
3 Monte Carlo Simulations
In order to verify the possibility of specification searching, we elaborate a Monte Carlo exercise
in which we generate 5,000 data sets and, for each one of them, test the null hypothesis of no
effect whatsoever adopting several different specifications. Conditional on a given specification, in
our simulations this placebo test should provide a rejection rate of α% under the null for a α%
significance test by construction. We are interested, however, in the probability of rejecting the null
hypothesis at the 5%-significance level for at least one specification. If different specifications result
in wildly different SC estimators, then the probability of finding one specification that rejects the
null at α% can be significantly higher than α%. In the extreme case in which we have K different
specifications and these specifications lead to independent estimators, this probability would be
given by 1− (1− α)K , where K is the number of different specifications.19 In this case, such lack
of guidance about which specifications should be used could generate substantial opportunities for
specification searching. In contrast, if different SC specifications lead to similar SC weights, then
this rejection rate will be close to α% and the risk of specification searching would be very low.
We consider two data generating processes. In Section 4 we consider placebo simulations with the
CPS.
In the first data generating process (DGP), we consider a linear factor model in which all units
19Lovell (1983) provides a similar formula, but considering the decision on which variables to include in a regression
model.
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are divided into groups that follow different stationary time trends.
Y 0j,t = δt + λ
k
t + j,t (8)
for some k = 1, ...,K. We consider the case in which J + 1 = 20 and K = 10. Therefore, units
1 and 2 follow the trend λ1t , units 3 and 4 follow the trend λ
2
t , and so on. We consider that λ
k
t is
normally distributed following an AR(1) process with 0.5 serial correlation parameter, δt ∼ N(0, 1)
and j,t ∼ N(0, 0.1).
In our second DGP, we modify the linear factor model such that a subset of the common factors
are non-stationary. In this case, we consider DGP which includes a non-stationary trend φrt that
follows a random walk:
Y 0j,t = δt + λ
k
t + φ
r
t + jt (9)
for some k = 1, ...,K and r = 1, ..., R. We consider in our simulations K = 10 and R = 2.
Therefore, units j = 2, ..., 10 follow the same non-stationary path φ1t as the treated unit, although
only unit j = 2 also follows the same stationary path λ1t as the treated unit.
In both models, we impose that there is no treatment effect, i.e., Yj,t = Y
0
j,t = Y
1
j,t for each
time period t ∈ {1, ..., T0}. We fix the number of post-treatment periods T − T0 = 10 and we vary
the number of pre-intervention periods in the DGPs, T0 ∈ {12, 32, 100, 400}. In the Appendix, we
consider variations in our stationary model (8) by setting (i) j,t ∼ N(0, 1), (ii) K = 2, or (iii)
including time-invariant covariates. We find similar results as the ones presented in the main text.
We calculate the SC estimator using the following six specifications that differ only in the linear
combinations of pre-treatment outcome values used as predictors:20
1. Pre-treatment outcome mean: Xj = [
∑T0
t=1 Yj,t/T0]
2. All pre-treatment outcome values: Xj = [Yj,1 · · ·Yj,T0 ]′
3. The first half of the pre-treatment outcome values: Xj =
[
Yj,1 · · ·Yj,T0/2
]′
20In order to compute the SC estimator, we use the Synth package in R. (See Abadie et al. (2011) for details.) This
package solves the nested minimization problem described by equations (3) and (4). We specify the optimization
method to be BFGS only and use optimization routine Low Rank Quadratic Programming when Interior Point
optimization routine does not converge.
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4. The first three fourths of the pre-treatment outcome values: Xj =
[
Yj,1 · · ·Yj,3T0/4
]′
5. Odd pre-treatment outcome values: Xj =
[
Yj,1 Yj,3 · · ·Yj,(T0−3) Yj,(T0−1)
]′
6. Even pre-treatment outcome values: Xj =
[
Yj,2 Yj,4 · · ·Yj,(T0−2) Yj,T0
]′
In order to simplify the presentation of our results, we do not consider in our MC simulations
the use of time-invariant covariates, as is commonly used in specifications that rely on the pre-
treatment outcome mean. In Appendix B we show that our results remain valid if we consider
specifications that use time-invariant covariates as economic predictors in addition to functions of
the pre-treatment outcomes.
For each specification, we run a permutation test using the RMSPE test statistic proposed in
Abadie et al. (2010) and reject the null at 5%-significance level if the treated unit has the largest
RMSPE among the 20 units. By construction, this leads to a 5% rejection rate when we look at
each specification separately. We are interested, however, in the probability that we would reject
the null at the 5%-significance level in at least one specification. This is the probability that a
researcher would be able to report a significant result even when there is no effect if she were to
engage in specification searching. If all different specifications result in the same synthetic control
unit, then we would find that the probability of rejecting the null in at least one specification would
be equal to 5% as well. However, this probability may be higher if the synthetic control weights
depend on specification choices.
We present in columns 1 and 2 of Table 1 the probability of rejecting the null at 5% and at 10%
significance levels in at least one specification for the stationary model. Columns 3 and 4 present
the same results for the non-stationary model.21 With T0 = 12, a researcher considering these six
different specifications would be able to report a specification with statistically significant results at
the 5% level with probability 12.7% for the stationary model and 12.4% for the non-stationary. If we
consider 10% significance tests, then the probability of rejecting the null in at least one specification
would be up to 22.5% and 22.1%, respectively for the stationary and the non-stationary models.
Therefore, with few pre-treatment periods, a researcher would have substantial opportunities to
select statistically significant specifications even when the null hypothesis is true. Importantly, note
21See table A.1 for results using different data generating processes.
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that it is not unusual to have SC applications with as few as 12 pre-intervention periods.22
If the variation in the synthetic control weights across different specifications vanishes when the
number of pre-treatment periods goes to infinity, then we would expect this probability to get closer
to 5% once the number of pre-treatment periods gets large. In this case, all different specifications
would provide roughly the same synthetic control unit and, therefore, the same treatment effect
estimate. The results in Table 1 show that the probabilities of rejecting the null are still significantly
higher than the test size even when the number of pre-intervention periods is large. In a scenario
with 400 pre-intervention periods, in the non-stationary model it would be possible to reject the
null in at least one specification 11.8% (21.4%) of the time for a 5% (10%) significance test.23 These
results suggest that specification searching remains a problem for the SC method even when the
number of pre-intervention periods is remarkably large for empirical applications.
In the previous exercise, we assumed that the researcher would be able to choose any of the 6
specifications we considered in our MC simulations. However, Abadie et al. (2010) and Abadie et al.
(2015) emphasize that the SC control estimator should only be used in the situations with good
pre-treatment fit, i.e., in situations in which the weighted average of the controls’ pre-treatment
outcomes is a good approximation for the treated pre-treatment outcome. It is important, therefore,
to check whether the specification-searching problem we identified in the SC method arises because
we allow the researcher to choose specifications that provide a poor pre-treatment fit. We consider
a pre-treatment normalized mean squared error index to determine whether a specification provides
a good pre-treatment fit:24
22See, for example, Abadie & Gardeazabal (2003), Kleven et al. (2013), Kreif et al. (2015), Smith (2015), Ando
(2015), Liu (2015), Sills et al. (2015), Billmeier & Nannicini (2013), Bohn et al. (2014), Cavallo et al. (2013), Hinrichs
(2012), Montalvo (2011), Li (2012) and Hosny (2012).
23Note that the probability of specification searching is not monotonic in T0. This happens because, with a very
small T0, the chance that a pre-treatment MSPE is close to zero is very high. Since there is a high correlation of
pre-treatment MSPE across specifications, it is likely that one unit will have a pre-treatment MSPE close to zero
for many specifications. This implies that this unit will have a large test statistic for all these specifications, so the
placebo test will reject the null for these specifications most of the time. As T0 increases, the probability of having a
pre-treatment MSPE close to zero will be small.
24This measure is very similar to the “pretreatment fit index” proposed by Adhikari & Alm (2016). These authors
propose a measure that is the ratio between the squared root of the mean squared predicted error (the numerator
of 1 − R˜2) and
√∑T0
t=1 Y
2
1t
T0
. The advantage of our measure relative to the one proposed by Adhikari & Alm (2016)
is that our measure is invariant to linearly additive changes. Dube & Zipperer (2015) also propose a pre-treatment
fit criterion that is equal to the numerator of our measure, the root of the mean squared error predictor between
the synthetic and the actual outcomes in the pre-treatment period. However, differently from our suggestion, their
measure is not scale invariant.
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R˜2 = 1−
∑T0
t=1
(
Y1,t − Ŷ N1,t
)2
∑T0
t=1
(
Y1,t − Y 1
)2 (10)
where Y 1 =
∑T0
t=1 Y1,t
T0
. If this measure is one, then we have a perfect fit.25
In order to capture a good fit, we consider two thresholds for R˜2, R˜2 > 0.80 and R˜2 > 0.95.
Considering these two thresholds, panel A of Table 2 shows the probability of finding a good pre-
treatment fit for at least one of the six specifications.26 The probability of finding specifications
with a good pre-treatment fit depends crucially on how we define whether a specification provided a
good fit and on whether we consider a stationary or a non-stationary model. We present in columns
1 and 2 the results for the stationary model. With a moderate T0, the probability of finding at
least one specification with good fit is close to one when we consider the weaker definition of good
fit, and close to zero when we consider the more stringent definition. Even when we consider the
weaker definition of good fit, it is interesting to note that the average number of specifications with
good fit is close to 5 (panel B of Table 2). This happens because the probability of having a good
fit for the specification that uses the pre-treatment mean as economic predictor is relatively low
(panel C of Table 2). We present in columns 3 and 4 the results for the non-stationary model.
In this case, the probability of having at least one specification with a good fit is close to one
even when we consider the more stringent definition of good fit. Also, there is a high probability
that all specifications (including the specification that uses the pre-treatment mean as economic
predictor) provide a good fit, especially when T0 is large. This happens because, with large T0, the
non-stationary factors dominate the variance of Y1,t. Since the SC estimator is extremely efficient
in controlling for the non-stationary factors (see Ferman & Pinto (2016)), it will usually provide a
good pre-treatment fit.
Given these definitions of good fit, we present in Table 3 the probabilities of rejecting the
null in at least one specification when we restrict the researcher to consider only specifications
that provide a good pre-treatment fit.27 Note that the possibilities for specification searching in
the non-stationary model (columns 3 and 4) are virtually the same as when we do not restrict for
specifications with a good pre-treatment fit, especially when T0 is large (columns 3 and 4 of Table 1).
25Note that, differently from the standard R2 measure, R˜2 can be negative.
26See table A.2 for results using different data generating processes.
27See table A.3 for results using different data generating processes.
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This is not surprising, given that all specifications will usually provide a good pre-treatment fit in
this model. For the stationary model (columns 1 and 2 of Table 3), the specification-search problem
is attenuated when we restrict to specifications with a good fit if we use the more lenient definition
of good fit (panel A). In practice, in this case the restriction of considering only specifications
with a good fit prevents the researcher from choosing the specification that uses the pre-treatment
mean as economic predictor, whose weights, as we show below, are very different from the ones
chosen by the other specifications. If we consider the more stringent definition of good fit, however,
then the probability of rejecting the null in at least one specifications is substantially higher (panel
B). This happens because, if we consider that the SC method should only be used when the pre-
treatment fit is good (as suggested in Abadie et al. (2010) and Abadie et al. (2015)), then there
is a low probability of finding a good fit for at least one specification and we would only consider
specifications such that the denominator of the test statistic for the treated unit is close to zero.
Since the test statistic for the placebo units are not conditional on a good pre-treatment, this leads
to over-rejection, as shown in Ferman & Pinto (2017).
Overall, these results suggest that restricting the researcher to consider only specifications with
a good fit does not necessarily attenuate the specification-searching problem. On the one hand, if
conditioning on a good fit does not actually restrict the set of options a researcher has (as happens
with our non-stationary model), then we have the same results as in the unconditional case. On
the other hand, if conditioning severely restricts the set of options, then we have over-rejection
because the test statistic for the treated unit is conditional on a denominator that is close to zero,
while the test statistics for the placebo units are unconditional.
The results so far indicate that different specifications can provide substantially different SC
estimators. An interesting feature of our MC simulations is that the SC estimator should assigned
positive weights only for unit 2 (which has the same factor loadings of unit 1), so we can actually
calculate the proportion of weights that is misallocated for each specification. We present in
columns 1 to 6 of Table 4 the proportion of misallocated weights for each specification in different
scenarios.28 Interestingly, specification 1 (which uses the pre-treatment mean as economic predictor)
misallocates substantially more weights relative to the other specifications. For the stationary
model (panel A), with T0 = 12, specification 1 misallocates more than 80% of the weights, while
28See table A.4 for results using different data generating processes.
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the misallocation for other specifications ranges from 23% to 29%. The misallocation of weights
decreases with T0 for all specifications, except for specification 1. Results are qualitatively the
same for the non-stationary model (panel B). These results suggest that using the pre-treatment
outcome mean might not capture the time-series dynamics of the units, which is the main goal of
the SC method.29
We also calculate a measure of variability of weights. For each unit in the donor pool we look
for the specifications that allocate the most and the least weight for this unit. Then we take the
maximum value of this difference across units in the donor pool. We present this measure in column
7 of Table 4.30 Interestingly, this measure does not decrease in T0, suggesting that increasing T0
does not imply that different SC specifications will lead to similar SC estimators. If we consider
this measure excluding specification 1, however, then it decreases in T0 (column 8 of Table 4).
These results indicate that, as T0 increases, the SC estimators using specifications 2 to 6 become
more similar, which is consistent with our results presented in Proposition 1. However, the SC
estimator using specification 1 can be considerably different from the SC estimators using the other
specifications even when T0 is large. This result is intuitive, given that specifications 2 to 6 exploit
the time-series dynamics of the data, while specification 1 does not.31
Given that the specification that uses the pre-treatment mean as the economic predictor stands
out by misallocating significantly more weights, in Table 5 we consider the specification-searching
possibilities excluding specification 1.32 Excluding specification 1 significantly attenuates the
specification-searching problem, especially when the number of pre-treatment periods is large, al-
though it does not completely solve the problem.33 This attenuation in the specification-searching
problem is not simply because we are considering five specifications instead of six. If we exclude,
29In specifications that use other covariates in addition to the pre-treatment mean, the matrix V would be chosen to
minimize the pre-treatment MSPE in the second step of the optimization process, so this estimator would somewhat
take the time-series dynamics of the outcome into account. However, this would be very limited because the first
minimization problem can severely restrict the set of possible weights W∗(V ) that may be chosen in the second step,
as suggested in Ferman & Pinto (2016).
30See table A.4 for results using different data generating processes.
31In Appendix B we show that specification 1 can fail to properly exploit the time-series dynamics of the data even
if we also include time-invariant covariates as economic predictors. In this case, it will still remain different from the
specifications that use pre-treatment outcome lags as economic predictors, even when the number of pre-treatment
periods is large. Therefore, our result that the possibilities of specification searching may not diminish with the
number of pre-treatment periods when we consider the specification that uses the pre-treatment outcome mean as
economic predictor remains valid even if we consider the addition of time-invariant variables as economic predictors.
32See table A.5 for results using different data generating processes.
33The only exception is when we consider the stationary model conditional on a good fit with R˜2 > 0.95. This
happens because, in this case, there is a low probability that we find at least one specification with a good fit.
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for example, specification 2 instead of specification 1, then there is virtually no change in the
specification-search problem relative to the case that we consider six specifications (Appendix Ta-
ble A.6).
4 Simulations with Real Data
The results presented in Section 3 suggest that different specifications of the SC method can
generate significant specification-searching opportunities. We now check whether the results we find
in our MC simulations are also relevant when we consider real datasets by conducting simulations
of placebo interventions with the Current Population Survey (CPS). We use the CPS Merged
Outgoing Rotation Groups for the years 1979 to 2014. Following Bertrand et al. (2004), we extract
information on employment status and earnings for women between ages 25 and 50. We also
consider in a separate set of simulations information on men in the same age range. Before we
proceed to the placebo simulations, we briefly discuss the raw data for these outcome variables.
There are important distinctions in the time series characteristics when we consider information for
men versus women and when we consider log wages versus employment. Figures 1a and 1b present
the time series of log wages for all US states, respectively for men and women. As expected, the
time series of log wages is non-stationary and increasing for both men and women. These graphs
suggest that there is a strong non-stationary factor that affects all states in the same way. Figures
1c and 1d present the time series of employment for all US states, respectively for men and women.
In this case, the time series for men should be closer to our stationary model from Section 3, while
the time series for women has an increasing trend in the 80s and 90s.
We first consider simulations with 12 pre-intervention periods, 4 post-intervention periods, and
20 states. In each simulation, we randomly select one treated and 19 control states out of the 51
states (including Washington, D.C.) and then we randomly select the first period between 1979 and
1999. Then we consider simulations with 32 pre-intervention periods, 4 post-intervention periods,
and 20 states. In this case, we randomly select 20 states and use the entire 36 years of data. In
each scenario, we run 5,000 simulations using either employment or log wages as the dependent
variable and test the null hypothesis using the same six specifications of Section 3.
We start presenting the probability of finding specifications with a good fit in Table 6. When
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the outcome variable is log wages, the probability of having at least one specification with a good
fit is close to one, especially when we consider T0 = 32 (columns 1 to 4, panel A). Also, when we
consider T0 = 32, the number of specifications with a good fit is close to 6, which suggests that
there is a high probability that all specifications will provide a good fit (columns 1 to 4, panel B).
These results are consistent with our MC simulations considering that the log wages series appear
to have important non-stationary common factors. The probability of finding specifications with a
good fit is lower when we consider employment instead of log wages as outcome variable, and even
lower when we consider men relative to women. This is consistent with the employment time series
for men being closer to a stationary process.
We present in Table 7 the probabilities of rejecting the null in at least one specification.34 In
panel A, we present the unconditional specification-searching probabilities. The results are very
similar to our findings in the MC simulations. With T0 = 12, depending on the sample and outcome
variable, there is 10-12% probability of finding a specification with statistically significant results
at 5% and a 19-21% probability of finding a specification with statistically significant results at
10%. With T0 = 32 these probabilities are slightly lower, but still significantly higher than the test
nominal size. In panels B and C we present results restricting the choices to specifications with a
good pre-treatment fit. As in our MC simulations, conditioning on a good fit does not attenuate
the specification-searching problem. When we consider log wages as outcome variable, conditioning
does not affect much these probabilities, as most specifications provide a good fit, especially when
T0 = 32. When we consider employment as outcome variable, conditioning leads to over-rejection
because there is a high probability that no specification provides a good fit and the surviving
specifications present a pre-treatment fit (the denominator of the test statistic) that is much lower
than the pre-treatment fit of the control units, that are not restricted to have a good fit. These
results suggest that specification-searching possibilities in SC applications can be relevant in real
applications of the SC method.
We also consider in Table 8 the specification-searching probabilities excluding the specification
that uses the pre-treatment mean as economic predictor. Similar to our MC simulations, excluding
this specification attenuates the specification-searching problem, although it does not completely
34Standard errors for these simulation results are clustered at the treated-state level, in order to take into account
that the simulations are not independent.
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solve the problem. With T0 = 32, the probability of rejecting the null at 5% in at least one
specification ranges from 7% to 7.9% depending on the sample and outcome variable, and in no case
we can reject that this probability is different from the nominal test size. Again, this attenuation
is not a simple mechanical effect due to the fact that we are considering fewer specifications. In
Appendix Table A.7, we show that there is virtually no change in the probabilities of rejecting the
null in at least one specification when we exclude specification 2 (instead of specification 1) relative
to the case where we consider all six specifications.
5 Recommendations
The specification-searching problem we identify arises from a lack of consensus about which
specifications should be used in SC applications. Our first recommendation is that researchers
should only consider specifications that capture the dynamic of the outcome of the treated unit
in the pre-treatment period, because our results suggest that the specification-searching problem
is magnified by specifications with undesirable properties, such as the specification that uses only
the mean pre-treatment outcome as economic predictor. If we discard this specification, then the
specification-searching problem is attenuated, especially if we have a large number of pre-treatment
periods, even though it does not solve the problem completely.
We also recommend that researchers applying the SC should report results for different spec-
ifications. However, even if a researcher present results for all possible SC specifications with an
hypothesis test for each specification, this would not provide a valid hypothesis test. If the decision
rule is to reject the null if the test rejects in all specifications, then we could end up with a very
conservative test (Romano & Wolf (2005)).35 If the decision rule is to reject the null if the test
rejects in at least one specification, then we would be back in the situation where we over-reject the
null. One possible solution is to base the inference procedure on a new test statistic that is a func-
tion that combines all the test statistics for the individual specifications, as suggested by Imbens
& Rubin (2015). Although this function can be non-linear, if it is simply a weighted average of the
test statistics for individual specifications, then Christensen & Miguel (2016) and Cohen-Cole et al.
35When we adopt this decision rule in our MC simulations, then probability of rejecting the null at 5% for all
specifications is lower than 1% in all scenarios. If we discard specification 1, then this rejection rate ranges from 1%
when T0 = 12 to 2.8% when T0 = 400.
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(2009) suggest using the same weights to compute a weighted average of the point-estimator of each
specification and using this weighted average as an estimate that incorporates model uncertainty.
Another possibility is to consider a criterion for choosing among all possible specifications. If
one restricts attention to only one specification that is chosen based on an objective criterium,
without the need of subjective decisions by the researcher, then the possibility for specification
searching would be limited, at least in this dimension. One such possibility is to follow Dube &
Zipperer (2015) and choose the specification that minimizes the mean squared prediction error
(MSPE) for the post-intervention periods for the placebo estimates.
6 Empirical Applications
We analyze the possibilities for specification searching and the implementability of our recom-
mendations in two empirical examples.
6.1 The resource curse exorcised: Evidence from a panel of countries (Smith
(2015))
Smith (2015) evaluates the impact of major natural resource discoveries since 1950 on GDP
per capita using different methods, including the synthetic control method.36 Major oil and gas
discoveries happened in Equatorial Guine and Equator in 1992 and 1972 respectively, implying that
pre and post-treatment periods are 1950-1991 and 1992-2008 for the first country and 1950-1971
and 1972-2008 for the second one. While the donor pool for Equatorial Guine consists of Sub-
Saharan African Countries (Benin, Burkina Faso, Burundi, Cameroon, Cape Verde, Central African
Republic, Chad, Cote d’Ivoire, Gambia, Ghana, Guinea, Kenya, Lesotho, Liberia, Madagascar,
Malawi, Mali, Mauritania, Mauritius, Mozambique, Namibia, Niger, Rwanda, Senegal, Somalia,
Sudan, Swaziland, Tanzania, Togo, Uganda, Zambia, Zimbabwe), the donor pool for Ecuador
consists of Latin American and Caribbean countries (Costa Rica, Cuba, Dominican Republic, El
Salvador, Guatemala, Honduras, Jamaica, Nicaragua, Panama, Paraguay, Puerto Rico, Uruguay).
We estimate the impact of major oil and gas discoveries on GDP per capita using the synthetic
control method with twelve different specifications. Specifically, we test six different specifications
36Following the best practices in terms of transparency and replicability, he made his dataset and replication files
available online (http://www.brockdsmith.com/research.html).
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that differ in which functions of the pre-treatment periods are included and, for each one of them, we
either include the covariates ethnic fragmentation and population size one year before the discovery
or not. Our the six basic specifications are:37
1. Original Specification (Even pre-treatment outcome values): Xj =
[
Yj,(T0−6) Yj,(T0−4) Yj,(T0−2) Yj,T0
]′
2. Pre-treatment outcome mean: Xj = [
∑T0
t=T0−6 Yj,t/7]
3. All pre-treatment outcome values: Xj =
[
Yj,(T0−6) · · ·Yj,T0
]′
4. The first half of the pre-treatment outcome values: Xj =
[
Yj,(T0−6) · · ·Yj,(T0−4)
]′
5. The first three fourths of the pre-treatment outcome values: Xj =
[
Yj,(T0−6) · · ·Yj,(T0−2)
]′
6. Odd pre-treatment outcome values: Xj =
[
Yj,(T0−5) Yj,(T0−3) Yj,(T0−1)
]′
where T0 = 1991 for Equatorial Guine and T0 = 1971 for Ecuador.
Table 9 shows the p-value and our goodness of fit measure for each specification and each
country. On the one hand, the results for Equatorial Guinea are robust to specification searching,
since all specifications provide treatment effect estimates that are significant at the 5%-level. On
the other hand, the results for Ecuador show that the researcher could try different specifications
and pick one whose result is significant. In particular, all twelve specifications have a good fit
(R˜2 > 0.80), but only two of them are significant (specifications (2b) and (6b)), implying that the
researcher could, potentially, report a false-positive result.38
We now test our recommendations in these particular applications. First of all, by presenting
results for more than one specification as we do in Table 9, a sensible conclusion would be that
major oil and gas discoveries had a significant effect on Equatorial Guinea’s GDP per capita even
though there is no evidence of such effect on Ecuador’s GDP per capital. Figure 2 shows that
37Although the number of pre-treatment years is larger than seven, we followed Smith (2015) and considered for
this exercise different specifications using only seven years of pre-treatment data in the first minimization problem
(equation (3)) while accounting for the entire pre-treatment period in the second minimization problem (equation
(4)). Had we considered only seven years of pre-treatment data in the second step, we would reach similar conclusions
to the ones in the main text. Had we considered the same specifications using the full pre-treatment data in the first
step, then we would fail to reject the null for all specifications. This is consistent with our result that the variation
between specifications that use pre-treatment outcome lags as economic predictor diminishes when the number of
pre-treatment periods increases. Results are available upon request.
38 We stress that the specification considered by Smith (2015) is not one of these two that would have led him to
conclude that there is a significant effect.
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this conclusion is reasonable since, in the case of Equatorial Guinea, we find that all specifications
with a good fit have estimates of similar magnitude while, in the case of Ecuador, our results vary
widely across specifications. The next step is to test the null hypothesis using a test statistics that
combine the test statistics of all specifications. Restricting ourselves to specifications with good fit
(R˜2 > 0.80), we find that the p-value of a test that uses the mean of the RMSPE statistic across
specifications, as suggested by Imbens & Rubin (2015), is equal to 0.031 and 0.308 for Equatorial
Guinea and Ecuador, corroborating our conclusion that the treatment effect is positive in the first
case and zero in the second one. Now, following the suggestion of Christensen & Miguel (2016)
and Cohen-Cole et al. (2009), figure 3 shows the average treatment effect across specifications
with good fit as a black line and the associated placebo effects as gray lines. Clearly, the effects for
Equatorial Guinea and Ecuador are, respectively, large and small when compared to their empirical
distributions. Finally, we apply the MSPE criterion suggested by Dube & Zipperer (2015) to select
only one specification. For Equatorial Guinea, we find that specification 5b (first three-fourths
of pre-treatment outcome values without covariates) minimizes the MSPE criterion, and the the
p-value for this specification is 0.031 . For Ecuador, we find that specification 5b (first three-fourths
pre-treatment outcome values without covariates) minimizes the MSPE criterion, and the p-value
for this specification is 0.308. Figure 4 shows the treatment effect and the placebo effects for
specifications 5b for Equatorial Guinea and Ecuador, respectively.
The results based on the recommendations by Imbens & Rubin (2015), Christensen & Miguel
(2016) and Cohen-Cole et al. (2009) point all to the same direction. Therefore, a reasonable
conclusion would be that the treatment effect is significant in the case of Equatorial Guinea and
statistically zero in the case of Ecuador. Importantly, without following these recommendations,
the results for Ecuador point out that it would be possible to find particular specifications with
a good pre-treatment fit that would lead the researcher to conclude that the effect for Ecuador is
statistically significant.
6.2 Synthetic Control Methods for Comparative Case Studies: Estimating the
Effect of California’s Tobacco Control Program (Abadie et al. (2010))
Abadie et al. (2010) evalute the effect of Proposition 99, a large-scale tobacco control program
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that California implemented in 1988, on annual per-capita cigarette sales.39 The pre and post-
treatment periods are 1970-1988 and 1989-2000. The donor pool includes thirty-eight American
states (Alabama, Arkansas, Colorado, Connecticut, Delaware, Georgia, Idaho, Illinois, Indiana,
Iowa, Kansas, Kentucky, Louisiana, Maine, Minnesota, Mississippi, Missouri, Montana, Nebraska,
Nevada, New Hampshire, New Mexico, North Carolina, North Dakota, Ohio, Oklahoma, Pennsyl-
vania, Rhode Island, South Carolina, South Dakota, Tennessee, Texas, Utah, Vermont, Virginia,
West Virginia, Wisconsin, Wyoming).
We estimate the impact of Proposition 99 on California’s annual per-capita cigarette sales
using the synthetic control method with fourteen different specifications. Specifically, we test seven
different specifications that differ in which functions of the pre-treatment periods are included
and, for each one of them, we either include the covariates average retail price of cigarettes, per
capita state personal income (logged), percentage of the population age 15–24, and per capita beer
consumption or not. The seven basic specification are (1) original specification by Abadie et al.
(2010) (outcome values for 1975, 1980 and 1988), (2) pre-treatment outcome mean, (3) all pre-
treatment outcome values, (4) the first half of the pre-treatment outcome values, (5) the first
three fourths of the pre-treatment outcome values, (6) odd pre-treatment outcome values, (7) even
pre-treatment outcome values.
Table 10 shows the p-value and our goodness of fit measure for each of the 14 specifications we
considered. Note that quality of the fit varies widely across specifications: eight of them fit the
data very closely (R˜2 ≥ 0.975), five of them have an intermediate value for our measure of goodness
of fit (0.80 < R˜2 < 0.975) and one of them fit the data very poorly (R˜2 ≤ 0.80). Most importantly,
all specifications with good fit have significant estimates whose magnitude is similar according to
figure 5, although p-values vary from 0.026 (the p-value in the specification considered in Abadie
et al. (2010)) to 0.077 depending on the specification.
Now, we test the null hypothesis using a test statistic that combine the test statistics of all
specifications. Restricting ourselves to specifications with a fit as good as the original specification
(R˜2 > 0.975), we find that the p-value of a test that uses the mean of the RMSPE statistic across
specifications, as suggested by Imbens & Rubin (2015), is equal to 0.077, which is larger than the
39Following the best practices in terms of transparency and replicability, they made their dataset and replication
files available through the command synth in the software Stata.
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p-value of the original specification (0.026). Hence, the treatment effect is still significant even
though the test statistic for California does not stands out as the largest one among all placebo
runs as it does when we consider the original specification. Additionally, figure 3 shows the average
treatment effect across specifications with good fit as a black line and the associated placebo effects
as gray lines following the suggestion of Christensen & Miguel (2016) and Cohen-Cole et al. (2009).
Note that the treatment effects for California seem to be larger (or, at least, more stable) than the
placebo effects.
Finally, we apply the MSPE criterion suggested by Dube & Zipperer (2015) to select only one
specification. We find that specification 6a (odd pre-treatment outcome values) minimizes the
MSPE criterion. The p-value for this specification is 0.026. This result is consistent with the one
reached by the method suggested by Imbens & Rubin (2015), although we would reject the null at
a lower significance level.
Overall, our results suggest that the effect of the California’s tobacco control program is sig-
nificantly different from zero, although the test statistic for California is not always the largest
one among all placebo runs when we consider different specifications, even if we consider only
specifications that provide a good pre-treatment fit.
7 Conclusion
We show that a lack of specific guidance on how to choose among different SC specifications
creates the potential for specification searching with synthetic controls. We also provide theoretical
results and empirical evidence from simulations that restricting the set of options a researcher has
when applying the SC method can substantially attenuate this specification-searching problem. We
move in this direction by showing that the specification that uses the average of the pre-treatment
outcome may fail to exploit the dynamics of the time series, which is the main goal of the SC
method. Discarding this specification significantly reduces the room for specification searching
when the number of pre-treatment periods is large, even though it does not completely solve the
problem. However, further research is necessary to determine in which circumstances one should
use all pre-treatment lags as economic predictors or only a subset of the pre-treatment outcome lags
(and, in this case, which subset should be used). Consequently, additional restrictions on the set
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of specifications applied researchers can use when employing the SC method in a given application
can further reduce the scope for specification searching with synthetic controls. Furthermore,
we also recommend that researchers report results using different specifications, and we suggest
alternatives to take into account the fact that the treatment effect can be estimated using different
specifications. Finally, we show that these recommendations can easily be implemented in practice,
providing clear conclusions about the significance of an estimate.
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Figure 1: Outcome trajectories in the CPS data
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Notes: We present the time series of log wages and employment rates for all US states separately by men and
women.
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Figure 2: Treatment Effects for All Specifications - Database from Smith (2015)
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Notes: Gray lines have R˜2 ≤ 0.80, dashed lines have 0.80 < R˜2 ≤ 0.95 and solid black lines have R˜2 > 0.95, where
R˜2 is defined by equation (10). The vertical lines denote the beginning of the post-treatment period.
Figure 3: Placebo Effects Using the Average Across Specifications - Database from
Smith (2015)
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Notes: We only consider specifications that satisfy R˜2 > 0.80 to compute the average treatment effect across spec-
ification, where R˜2 is defined by equation (10). Gray lines are the placebo effects of the control countries and the
black line is the treatment effect of the treated country. The vertical lines denote the beginning of the post-treatment
period.
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Figure 4: Placebo Effects Using the MSPE Criterion - Database from Smith (2015)
(a) Equatorial Guinea - Specification (6b)
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(b) Ecuador - Specification (2b)
1950 1960 1970 1980 1990 2000
−
50
00
0
50
00
10
00
0
G
ap
 in
 R
ea
l p
er
−c
ap
ita
 G
DP
 
 
((1
99
0 I
nt.
 G
K$
))
Notes: We only consider specifications that satisfy R˜2 > 0.80 when minimizing the MSPE criterion (Dube & Zipperer
(2015)) across specifications, where R˜2 is defined by equation (10). Gray lines are the placebo effects of the control
countries and the black line is the treatment effect of the treated country. The vertical lines denote the beginning of
the post-treatment period.
Figure 5: Treatment Effects for All Specifications - Database from Abadie et al. (2010)
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Notes: The solid black line is the original specification by Abadie et al. (2010), whose measure of goodness of fit is
R˜2 = 0.0975, where R˜2 is defined by equation (10). Gray lines have R˜2 ≤ 0.975 and dashed lines have R˜2 > 0.975.
The vertical line denotes the beginning of the post-treatment period.
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Figure 6: Placebo Effects Using the Average Across Specifications - Database from
Abadie et al. (2010)
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Notes: We only consider specifications that satisfy R˜2 > 0.0975 to compute the average treatment effect across
specification, where R˜2 is defined by equation (10) Gray lines are the placebo effects of the control state and the
black line is the treatment effect of California. The vertical line denotes the beginning of the post-treatment period.
Figure 7: Placebo Effects Using the MSPE Criterion (Specification 5a) - Database from
Abadie et al. (2010)
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Notes: We only consider specifications that satisfy R˜2 > 0.975 when minimizing the MSPE criterion (Dube &
Zipperer (2015)) across specifications, where R˜2 is defined by equation (10). Gray lines are the placebo effects of the
control states and the black line is the treatment effect of California. The vertical line denotes the beginning of the
post-treatment period.
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Table 1: Specification searching
Stationary Model Non-stationary Model
5% test 10% test 5% test 10% test
(1) (2) (3) (4)
T0 = 12 0.127 0.225 0.124 0.221
(0.005) (0.006) (0.005) (0.006)
T0 = 32 0.128 0.234 0.137 0.240
(0.005) (0.006) (0.005) (0.006)
T0 = 100 0.122 0.222 0.130 0.236
(0.005) (0.006) (0.005) (0.006)
T0 = 400 0.114 0.212 0.118 0.214
(0.005) (0.006) (0.005) (0.006)
Note: Rejection rates are estimated based on 5,000 observations and on
six specifications — (1) the mean of all pre-treatment outcome values, (2)
all pre-treatment outcome values, (3) the first half of the pre-treatment
outcome values, (4) the first three quarters of the pre-treatment out-
come values, (5) odd pre-treatment outcome values, and (6) even pre-
treatment outcome values. z% test indicates that the nominal size of
the analyzed test is z% and T0 is the number of pre-treatment periods.
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Table 2: Probability of good pre-treatment fit
Stationary model Non-stationary model
R˜2 > 0.80 R˜2 > 0.95 R˜2 > 0.80 R˜2 > 0.95
(1) (2) (3) (4)
Panel A: At least one specification with good fit
T0 = 12 0.942 0.262 0.988 0.609
(0.002) (0.004) (0.001) (0.004)
T0 = 32 0.994 0.091 1.000 0.818
(0.002) (0.004) (0.001) (0.004)
T0 = 100 1.000 0.003 1.000 0.997
(0.002) (0.004) (0.001) (0.004)
T0 = 400 1.000 0.000 1.000 1.000
(0.002) (0.004) (0.001) (0.004)
Panel B: # of specifications with good fit
T0 = 12 4.522 0.923 5.128 2.604
(0.012) (0.015) (0.008) (0.022)
T0 = 32 5.068 0.339 5.389 4.002
(0.012) (0.015) (0.008) (0.022)
T0 = 100 5.169 0.007 5.753 5.246
(0.012) (0.015) (0.008) (0.022)
T0 = 400 5.166 0.000 5.991 5.681
(0.012) (0.015) (0.008) (0.022)
Panel C: Specification 1 has a good fit
T0 = 12 0.162 0.015 0.300 0.073
(0.005) (0.001) (0.006) (0.006)
T0 = 32 0.164 0.005 0.394 0.131
(0.005) (0.001) (0.006) (0.005)
T0 = 100 0.169 0.000 0.753 0.268
(0.005) (0.001) (0.006) (0.005)
T0 = 400 0.166 0.000 0.991 0.681
(0.005) (0.001) (0.006) (0.006)
Note: Descriptive statistics are estimated based on 5,000 observations and
on six specifications — (1) the mean of all pre-treatment outcome values,
(2) all pre-treatment outcome values, (3) the first half of the pre-treatment
outcome values, (4) the first three quarters of the pre-treatment outcome
values, (5) odd pre-treatment outcome values, and (6) even pre-treatment
outcome values. T0 is the number of pre-treatment periods. Our measure
of goodness of fit is defined by equation (10). We consider two definitions
of good fit; R˜2 > 0.80 and R˜2 > 0.95.
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Table 3: Specification searching conditional on a good pre-treatment fit
Stationary Model Non-stationary Model
5% test 10% test 5% test 10% test
(1) (2) (3) (4)
Panel A: R˜2 > 0.80
T0 = 12 0.106 0.188 0.111 0.194
(0.004) (0.005) (0.005) (0.006)
T0 = 32 0.100 0.182 0.119 0.205
(0.004) (0.005) (0.005) (0.006)
T0 = 100 0.090 0.157 0.124 0.221
(0.004) (0.005) (0.005) (0.006)
T0 = 400 0.079 0.143 0.118 0.214
(0.004) (0.005) (0.005) (0.006)
Panel B: R˜2 > 0.95
T0 = 12 0.197 0.321 0.125 0.215
(0.011) (0.013) (0.006) (0.007)
T0 = 32 0.192 0.328 0.113 0.191
(0.019) (0.022) (0.005) (0.006)
T0 = 100 0.154 0.308 0.103 0.179
(0.110) (0.130) (0.004) (0.006)
T0 = 400 - - 0.107 0.191
- - (0.004) (0.006)
Note: Rejection rates are estimated based on 5,000 observations and on
six specifications — (1) the mean of all pre-treatment outcome values, (2)
all pre-treatment outcome values, (3) the first half of the pre-treatment
outcome values, (4) the first three quarters of the pre-treatment out-
come values, (5) odd pre-treatment outcome values, and (6) even pre-
treatment outcome values. z% test indicates that the nominal size of
the analyzed test is z% and T0 is the number of pre-treatment periods.
Our measure of goodness of fit is defined by equation (10). We consider
two definitions of good fit; R˜2 > 0.80 and R˜2 > 0.95.
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Table 4: Variability and Misallocation of weights
Misallocation of weights in specification: Variability of weights
1 2 3 4 5 6 All Exclude 1
(1) (2) (3) (4) (5) (6) (7) (8)
Panel A: Stationary Model
T0 = 12 0.811 0.226 0.260 0.290 0.243 0.247 0.736 0.317
(0.005) (0.002) (0.003) (0.003) (0.003) (0.003) (0.003) (0.003)
T0 = 32 0.810 0.147 0.143 0.180 0.141 0.142 0.763 0.181
(0.005) (0.001) (0.001) (0.002) (0.001) (0.001) (0.004) (0.001)
T0 = 100 0.812 0.110 0.099 0.124 0.099 0.099 0.774 0.115
(0.005) (0.001) (0.001) (0.001) (0.001) (0.001) (0.004) (0.001)
T0 = 400 0.813 0.091 0.086 0.096 0.086 0.085 0.769 0.069
(0.005) (0.000) (0.000) (0.001) (0.000) (0.000) (0.004) (0.000)
Panel B: Non-stationary Model
T0 = 12 0.807 0.192 0.219 0.249 0.209 0.212 0.753 0.287
(0.005) (0.002) (0.003) (0.003) (0.003) (0.003) (0.004) (0.003)
T0 = 32 0.812 0.117 0.122 0.151 0.120 0.119 0.784 0.165
(0.005) (0.001) (0.001) (0.002) (0.001) (0.001) (0.004) (0.001)
T0 = 100 0.814 0.086 0.081 0.099 0.081 0.082 0.794 0.107
(0.005) (0.001) (0.001) (0.001) (0.001) (0.001) (0.004) (0.001)
T0 = 400 0.818 0.073 0.070 0.077 0.070 0.071 0.792 0.070
(0.005) (0.000) (0.000) (0.001) (0.000) (0.000) (0.005) (0.000)
Note: The average of misallocated weights is based on 5,000 observations. The reasoning behind this variable is
the following: since, in our DGP, we divide units into groups whose trends are parallel only when compared to
units in the same group, the sum of the weights allocated to the units in the other groups is a measure of the
relevance given by the synthetic control method to units whose true potential outcome follows a different trajectory
than the one followed by the unit chosen to be the treated one. The average of variability of weights is based
on 5,000 observations and captures the average maximum difference of allocated weights across specifications.
Specification s is one of the specifications used to compute the synthetic control unit: (1) the mean of all pre-
treatment outcome values, (2) all pre-treatment outcome values, (3) the first half of the pre-treatment outcome
values, (4) the first three quarters of the pre-treatment outcome values, (5) odd pre-treatment outcome values,
and (6) even pre-treatment outcome values. T0 is the number of pre-treatment periods.
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Table 5: Specification searching - Excluding specification 1
Stationary Model Non-stationary Model
5% test 10% test 5% test 10% test
(1) (2) (3) (4)
Panel A: Unconditional
T0 = 12 0.105 0.189 0.106 0.187
(0.004) (0.005) (0.004) (0.005)
T0 = 32 0.099 0.180 0.110 0.186
(0.004) (0.005) (0.004) (0.005)
T0 = 100 0.087 0.152 0.098 0.167
(0.004) (0.005) (0.004) (0.005)
T0 = 400 0.077 0.140 0.080 0.141
(0.004) (0.005) (0.004) (0.005)
Panel B: Conditional on R˜2 > 0.80
T0 = 12 0.101 0.182 0.104 0.184
(0.004) (0.005) (0.004) (0.005)
T0 = 32 0.098 0.178 0.110 0.186
(0.004) (0.005) (0.004) (0.005)
T0 = 100 0.087 0.152 0.098 0.167
(0.004) (0.005) (0.004) (0.005)
T0 = 400 0.077 0.140 0.080 0.141
(0.004) (0.005) (0.004) (0.005)
Panel C: Conditional on R˜2 > 0.95
T0 = 12 0.192 0.316 0.124 0.214
(0.011) (0.013) (0.005) (0.007)
T0 = 32 0.187 0.326 0.111 0.188
(0.018) (0.022) (0.005) (0.006)
T0 = 100 0.154 0.308 0.098 0.168
(0.109) (0.129) (0.004) (0.005)
T0 = 400 - - 0.080 0.141
- - (0.004) (0.005)
Note: Rejection rates are estimated based on 5,000 observations and on
five specifications — (1) all pre-treatment outcome values, (2) the first
half of the pre-treatment outcome values, (3) the first three quarters
of the pre-treatment outcome values, (4) odd pre-treatment outcome
values, and (5) even pre-treatment outcome values. z% test indicates
that the nominal size of the analyzed test is z% and T0 is the number
of pre-treatment periods. Our measure of goodness of fit is defined by
equation (10). We consider two definitions of good fit; R˜2 > 0.80 and
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Table 6: Probability of good pre-treatment fit - CPS
Log wages Employment
Women Men Women Men
R˜2 > 0.80 R˜2 > 0.95 R˜2 > 0.80 R˜2 > 0.95 R˜2 > 0.80 R˜2 > 0.95 R˜2 > 0.80 R˜2 > 0.95
(1) (2) (3) (4) (5) (6) (7) (8)
Panel A: At least one specification
T0 = 12 0.913 0.573 0.875 0.410 0.284 0.033 0.156 0.017
(0.028) (0.043) (0.031) (0.044) (0.030) (0.011) (0.032) (0.008)
T0 = 32 0.963 0.950 0.982 0.906 0.655 0.042 0.066 0.000
(0.026) (0.028) (0.018) (0.032) (0.057) (0.024) (0.030) -
Panel B: # of specifications with good fit
T0 = 12 5.368 2.713 5.000 1.741 1.160 0.093 0.496 0.034
(0.176) (0.233) (0.194) (0.214) (0.135) (0.037) (0.115) (0.018)
T0 = 32 5.771 5.657 5.886 5.279 3.542 0.193 0.303 0.000
(0.160) (0.172) (0.112) (0.202) (0.327) (0.111) (0.143) -
Note: Descriptive statistics are estimated based on six specifications — (1) the mean of all pre-treatment outcome values, (2) all pre-
treatment outcome values, (3) the first half of the pre-treatment outcome values, (4) the first three quarters of the pre-treatment outcome
values, (5) odd pre-treatment outcome values, and (6) even pre-treatment outcome values — and on 5,000 observations for each outcome
variable (employment and log wages), for each sample (men and women) and number of pre-treatment periods (T0 ∈ {12, 32}).Our measure
of goodness of fit is defined by equation (10). We consider two definitions of good fit; R˜2 > 0.80 and R˜2 > 0.95.
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Table 7: Specification searching - CPS simulations
Log wages Employment
Women Men Women Men
5% test 10% test 5% test 10% test 5% test 10% test 5% test 10% test
(1) (2) (3) (4) (5) (6) (7) (8)
Panel A: Unconditional
T0 = 12 0.114*** 0.204*** 0.109*** 0.188*** 0.122*** 0.209*** 0.112*** 0.205***
(0.013) (0.019) (0.012) (0.016) (0.012) (0.016) (0.013) (0.018)
T0 = 32 0.102** 0.184** 0.097* 0.175** 0.092 0.166* 0.100** 0.191***
(0.026) (0.035) (0.026) (0.038) (0.030) (0.039) (0.023) (0.035)
Panel B: Conditional on R˜2 > 0.80
T0 = 12 0.123*** 0.219*** 0.119*** 0.201*** 0.201*** 0.331*** 0.253*** 0.408***
(0.013) (0.019) (0.012) (0.017) (0.023) (0.026) (0.028) (0.029)
T0 = 32 0.104** 0.187** 0.099* 0.178** 0.126* 0.210** 0.151 0.241
(0.027) (0.037) (0.027) (0.038) (0.042) (0.054) (0.080) (0.108)
Panel C: Conditional on R˜2 > 0.95
T0 = 12 0.163*** 0.275*** 0.171*** 0.280*** 0.403*** 0.522*** 0.417*** 0.595***
(0.016) (0.023) (0.017) (0.022) (0.052) (0.045) (0.046) (0.055)
T0 = 32 0.106** 0.189** 0.094* 0.178** 0.185*** 0.379*** - -
(0.027) (0.037) (0.025) (0.037) (0.043) (0.057) - -
Note: Rejection rates are estimated based on six specifications — (1) the mean of all pre-treatment outcome values, (2) all pre-
treatment outcome values, (3) the first half of the pre-treatment outcome values, (4) the first three quarters of the pre-treatment
outcome values, (5) odd pre-treatment outcome values, and (6) even pre-treatment outcome values — and on 5,000 observations
for each outcome variable (employment and log wages), for each sample (men and women) and number of pre-treatment periods
(T0 ∈ {12, 32}). z% test indicates that the nominal size of the analyzed test is z%. Our measure of goodness of fit is defined by
equation (10). We consider two definitions of good fit; R˜2 > 0.80 and R˜2 > 0.95. * means that we reject at 10% the null that
the probability of rejecting at least one specification at z% is equal to z%. ** means that we reject at 5%, while *** means that
we reject at 1%.
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Table 8: Specification searching excluding specification 1 - CPS simulations
Log wages Employment
Women Men Women Men
5% test 10% test 5% test 10% test 5% test 10% test 5% test 10% test
(1) (2) (3) (4) (5) (6) (7) (8)
Panel A: Unconditional
T0 = 12 0.100*** 0.178*** 0.096*** 0.165*** 0.105*** 0.183*** 0.100*** 0.181***
(0.012) (0.018) (0.011) (0.016) (0.011) (0.016) (0.012) (0.017)
T0 = 32 0.079 0.145 0.071 0.135 0.070 0.133 0.077 0.149
(0.022) (0.032) (0.021) (0.033) (0.025) (0.034) (0.019) (0.030)
Panel B: Conditional on R˜2 > 0.80
T0 = 12 0.108*** 0.193*** 0.106*** 0.183*** 0.198*** 0.322*** 0.251*** 0.406***
(0.012) (0.018) (0.011) (0.016) (0.023) (0.026) (0.027) (0.029)
T0 = 32 0.082 0.149 0.072 0.137 0.105 0.185* 0.151 0.241
(0.023) (0.033) (0.021) (0.033) (0.036) (0.049) (0.080) (0.108)
Panel C: Conditional on R˜2 > 0.95
T0 = 12 0.154*** 0.264*** 0.166*** 0.273*** 0.403*** 0.522*** 0.417*** 0.595***
(0.016) (0.022) (0.016) (0.022) (0.052) (0.045) (0.046) (0.055)
T0 = 32 0.083 0.151 0.076 0.142 0.185*** 0.379*** - -
(0.024) (0.033) (0.022) (0.034) (0.043) (0.057) - -
Note: Rejection rates are estimated based on five specifications — (1) all pre-treatment outcome values, (2) the first half of the
pre-treatment outcome values, (3) the first three quarters of the pre-treatment outcome values, (4) odd pre-treatment outcome
values, and (5) even pre-treatment outcome values — and on 5,000 observations for each outcome variable (employment and
log wages), for each sample (men and women) and number of pre-treatment periods (T0 ∈ {12, 32}). z% test indicates that the
nominal size of the analyzed test is z%. Our measure of goodness of fit is defined by equation (10). We consider two definitions
of good fit; R˜2 > 0.80 and R˜2 > 0.95. * means that we reject at 10% the null that the probability of rejecting at least one
specification at z% is equal to z%. ** means that we reject at 5%, while *** means that we reject at 1%.
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Table 9: Specification Searching - Database from Smith (2015)
Equatorial Guinea Ecuador
p-value R˜2 p-value R˜2
(1) (2) (3) (4)
(1a) 0.031 0.828 0.538 0.881
(1b) 0.031 0.744 0.769 0.804
(2a) 0.031 0.848 0.538 0.804
(2b) 0.031 0.657 0.077 0.972
(3a) 0.031 0.866 0.538 0.881
(3b) 0.031 0.797 0.385 0.975
(4a) 0.031 0.809 0.615 0.880
(4b) 0.031 0.790 0.231 0.972
(5a) 0.031 0.777 0.538 0.881
(5b) 0.031 0.832 0.308 0.975
(6a) 0.031 0.891 0.308 0.969
(6b) 0.031 0.536 0.077 0.970
# of Permutations 33 14
Note: We analyze twelve different specifications. The number of the spec-
ifications refer to: (1) even pre-treatment outcome values (original specifi-
cation by Smith (2015)), (2) the mean of all pre-treatment outcome values,
(3) all pre-treatment outcome values, (4) the first half of the pre-treatment
outcome values, (5) the first three quarters of the pre-treatment outcome
values and (6) odd pre-treatment outcome values. Specifications that end
with an a include the covariates ethnic fragmentation and population size
one year before the discovery, while specifications that end with an b do not
include covariates. Our measure of goodness of fit is defined by equation
(10).
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Table 10: Specification Searching - Database from Abadie et al. (2010)
Specification (1a) (1b) (2a) (2b) (3a) (3b) (4a) (4b)
p-value 0.026 0.077 0.077 0.077 0.077 0.077 0.026 0.051
R˜2 0.975 0.909 0.828 0.525 0.979 0.979 0.968 0.969
Specification (5a) (5b) (6a) (6b) (7a) (7b)
p-value 0.077 0.077 0.026 0.051 0.077 0.077
R˜2 0.976 0.974 0.978 0.978 0.979 0.978
Note: We analyze fourteen different specifications. The number of the specifications refer
to: (1) original specification by Abadie et al. (2010)), (2) the mean of all pre-treatment
outcome values, (3) all pre-treatment outcome values, (4) the first half of the pre-treatment
outcome values, (5) the first three quarters of the pre-treatment outcome values, (6) odd
pre-treatment outcome values and (7) even pre-treatment outcome values. Specifications
that end with an a include the covariates average retail price of cigarettes, per capita state
personal income (logged), percentage of the population age 15–24, and per capita beer con-
sumption, while specifications that end with an b do not include covariates. Our measure
of goodness of fit is defined by equation (10).
47
ONLINE APPENDIX
(NOT FOR PUBLICATION)
A Proofs of the main results
Proof of Proposition 1
Let W˜ = {Ŵ ∈ W|Ŵ ∈ arg minW∈W(X1 − X0W)′V(X1 − X0W) for some V ∈ V}, and
Q̂T0(W) =
1
T0
(Y1 −Y0W)′(Y1 −Y0W). Also, let fˆsT0(W,V) = (X1 −X0W)′V(X1 −X0W),
where Xj includes the predictors used in specification s when there are T0 pre-treatment periods.
The SC weights computed from the nested optimization problem proposed in Abadie et al.
(2010) can be defined by:
Ŵ(s, T0) = arg min
W∈W˜
Q̂T0(W) (11)
We want to show that Ŵ(s, T0)
p→ W¯. First, let V∗(s, T0) be a diagonal matrix with diag-
onal entries equal to 1 for pre-treatment outcome lags and 0 for other predictors when we con-
sider the predictors used in specification s with T0 pre-treatment periods. Then we have that
1
L(s,T0)
fˆsT0(W,V
∗(s, T0)) = 1L(s,T0)
∑
t∈I(s,T0)
(
Y 01,t − y0−1,t′W
)2
. By assumption 1 and by the fact
that L(s, T0)→∞ with T0, 1L(s,T0) fˆ sT0(W,V∗(s, T0)) converges uniformly in probability to Q0(W),
which is uniquely minimized at W¯. Let Ŵ(s, V ∗(s, T0), T0) = arg minW∈W 1L(s,T0) fˆ
s
T0
(W,V∗(s, T0)).
SinceW is compact, we have that Ŵ(s, V ∗(s, T0), T0) p→ W¯ when T0 →∞ (Theorem 2.1 of Newey
& McFadden (1994)).
We now show that the solution to the nested problem proposed in Abadie et al. (2010) will
also converge in probability to W¯. First, note that Ŵ(s, T0) always exist. According to Berge’s
Maximum Theorem (Ok 2007, p. 306), Ŵ (V) is a compact-value, upper hemicontinuous and closed
correspondence. As a consequence, W˜ is a compact set. To see that, take any sequence
{
W˜n
}
n∈N
such that W˜n ∈ W˜ for any n ∈ N. Since W˜ = ∪V ∈VŴ (V) by its definition, there exists Vn ∈ V
for each n ∈ N such that W˜n ∈ Ŵ (Vn). We also know that there exists a convergent subsequence
{Vnm}m∈N such that limm→+∞Vnm =: V ∈ V because V is a compact set. By the definition
of upper hemicontinuity (Stokey & Lucas 1989, p. 56), there exists a convergent subsequence{
W˜nml
}
l∈N
such that liml→+∞ W˜nml =: W ∈ Ŵ
(
V
)
⊂ ∪V ∈VŴ (V) = W˜, proving that W˜ is a
compact set. Consequently, Weierstrass’ Extreme Value Theorem guarantees that Ŵ(s, T0) exists.
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From assumption 1, we have that Q̂T0(W) converges uniformly to Q0(W) over W. There-
fore, for any  > 0, (i) uniform convergence of Q̂T0(W) implies that Q̂T0(Ŵ(s, V
∗(s, T0), T0)) <
Q0(Ŵ(s, V
∗(s, T0), T0)) + 3 and Q0(W¯) < Q̂T0(W¯) +

3 with probability approaching to one
(w.p.a.1), and (ii) convergence in probability of Ŵ(s, V ∗(s, T0), T0) and continuity of Q0(W) im-
plies that Q0(Ŵ(s, V
∗(s, T0), T0)) < Q0(W¯)) + 3 w.p.a.1. Therefore, Q̂T0(Ŵ(s, V
∗(s, T0), T0)) <
Q̂T0(W¯) +  w.p.a.1.
Suppose now that Ŵ(s, T0) does not converge in probability to W¯. Then ∃˜ > 0 such that
LimPr(|Ŵ(s, T0) − W¯| > ˜) 6= 0 when T0 → ∞. Since W is compact and Q0(W) is uniquely
minimized at W¯, then |Ŵ(s, T0)−W¯| > ˜ implies that ∃η > 0 such that Q0(Ŵ(s, T0)) > Q0(W¯)+
3η. Uniform convergence of Q̂T0(W) implies that Q̂T0(Ŵ(s, T0)) > Q0(Ŵ(s, T0))−η and Q0(W¯) >
Q̂T0(W¯)− η w.p.a.1. Therefore, Q̂T0(Ŵ(s, T0)) > Q̂T0(W¯) + η w.p.a.1.
However, if we set  = η, then we have Q̂T0(Ŵ(s, V
∗(s, T0), T0)) < Q̂T0(Ŵ(s, T0)) w.p.a.1,
which contradicts the fact that for all T˜0 we can always find T0 > T˜0 such that Ŵ(s, T0) ∈ W˜
with |Ŵ(s, T0)− W¯| > ˜ minimizes Q̂T0(W) with positive probability. Therefore, it must be that
Ŵ(s, T0) converges in probability to W¯.
Proof of Corollary 2
Notice that we can write each estimator as:
α̂1t (s, T0) = Y1t −
J+1∑
j=2
ŵj (s, T0)Yj,t for any s (12)
Using the result of proposition 1, under assumption 1:
α̂1t (s, T0)→d Y1t −
J+1∑
j=2
wjYj,t as T0 → α for any s (13)
Hence, for any s and s′ such that L(s, T0)→∞ and L(s′, T0)→∞ when T0 →∞:
∣∣∣α̂1t (s, T0)− α̂1t(s′ , T0)∣∣∣→p 0 (14)
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Proof of Corollary 3
Let y−j,t be the vector of outcomes at time t excluding unit j, Ŵj be the SC weights when
unit j is used as treated, and W¯j := arg minW∈W˜ Qj(W).
Conditional on {y1,t, ..., yJ+1,t}Tt=T0+1, if outcomes are continuous, then we can define {(1), ..., (J+
1)} such that, with probability one:40
1
T−T0
∑T
t=T0
(
y(1),t − y′−(1),tW¯(1)
)2
Q(1)(W¯)
> ... >
1
T−T0
∑T
t=T0
(
y(J+1),t − y′−(J+1),tW¯(J+1)
)2
Q(J+1)(W¯)
(15)
From proposition 1, we know that Ŵj
p→ W¯j and 1T0
∑T0
t=1
(
yj,t − y′−j,tŴj
)2 p→ Qj(W¯).
Therefore, the inequalities in 15 will remain valid w.p.a.1 when we consider the test statistics for
the placebo runs.
Sufficient Conditions for Assumption 1
Let y0t = (Y
0
1,t, ..., Y
0
J+1,t)
′. We show that the following assumption is sufficient for Assumption
1.
Assumption 2 {y0ty0t ′} is weakly stationarity, each element of {y0ty0t ′} has absolutely summable
covariances, and E
[
y0ty
0
t
′]
is non-singular.
Let At be one element of {y0ty0t ′}. Under Assumption 2, we can define E[At] = µ and E[(At −
µ)(At−j − µ)] = γj , where
∑∞
j=0 |γj | < ∞. Consider a subsequence {tk}k∈N with tk > tk−1. Note
that E
[
1
K
∑K
k=1Atk
]
= µ. We want to show that E
[
1
K
∑K
k=1 (Atk − µ)
]2 → 0 when K →∞. Note
that:
K2E
[
1
K
K∑
k=1
(Atk − µ)
]2
= (γ0 + γ|t1−t2| + ...+ γ|t1−tK |) +
+(γ|t2−t1| + γ0 + ...+ γ|t2−tK |) +
+...+ (γ|tK−t1| + γ|tK−1−t1| + ...+ γ0)
= Kγ0 +
K−1∑
k=1
 K∑
j=k+1
2γ|tj−tk|
 ≤ K|γ0|+ K−1∑
k=1
 K∑
j=k+1
2|γ|tj−tk||

40Continuous outcomes guarantees that ties will happen with probability zero.
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Let lim
∑T
j=0 |γj | = C. Now note that, for each k,
∑K
j=k+1 2|γ|tj−tk|| is the sum of a subsequence
of {|γj |}. Therefore, for any k, we have that
∑K
j=k+1 2|γ|tj−tk|| ≤
∑tK
j=1 2|γj | ≤ C. Therefore:
E
[
1
K
K∑
k=1
(Atk − µ)
]2
≤ 1
K
|γ0|+ K − 1
K2
C
which implies that E
[
1
K
∑K
k=1 (Atk − µ)
]2 → 0 when K →∞. Therefore, we have that all elements
of the pre-treatment averages of {y0ty0t ′} for any subsequence {tk}k∈N converge in probability to
their corresponding expected values.
Since 1K
∑K
k=1
(
Y 0j,tk − y0−j,tk
′
W
)2
is a linear combination of pre-treatment averages of elements
of {y0ty0t ′} for a given subsequence {tk}k∈N, for any W ∈ W, we have that:
Q˜K(W) ≡ 1
K
K∑
k=1
(
Y 0j,tk − y0−j,tk
′
W
)2 p→ E [(Y 0j,t − y0−j,t′W)2] (16)
where E
[(
Y 0j,t − y0−j,t′W
)2]
is continuous and strictly convex.
Finally, we show that this convergence in probability is uniform. For any W′,W ∈ W, using
the mean value theorem, we can find W˜ ∈ W such that:
∣∣∣Q˜K(W′)− Q˜K(W)∣∣∣ =
∣∣∣∣∣2
(
1
K
K∑
k=1
y0−j,tkY
0
j,tk
− 1
K
K∑
k=1
y0−j,tky
0
−j,tk
′
W˜
)
· (W′ −W)∣∣∣∣∣ (17)
≤
[(
2
∣∣∣∣∣
∣∣∣∣∣ 1K
K∑
k=1
y0−j,tkY
0
j,tk
∣∣∣∣∣
∣∣∣∣∣+
∣∣∣∣∣
∣∣∣∣∣ 1K
K∑
k=1
y0−j,tky
0
−j,tk
′
∣∣∣∣∣
∣∣∣∣∣× ∣∣∣∣∣∣W˜∣∣∣∣∣∣
) ∣∣∣∣W′ −W∣∣∣∣] 12(18)
Define BK = 2
∣∣∣∣∣∣ 1K ∑Kk=1 y0−j,tkY 0j,tk ∣∣∣∣∣∣+ ∣∣∣∣∣∣ 1K ∑Kk=1 y0−j,tky0−j,tk ′∣∣∣∣∣∣ ·C. Since W is compact, ∣∣∣∣∣∣W˜∣∣∣∣∣∣
is bounded, so we can find a constant C such that
∣∣∣Q˜K(W′)− Q˜K(W)∣∣∣ ≤ BK (||W′ −W||) 12 .
From assumption 2, BK converges in probability to a positive constant, so BK = Op(1). Note
also that E
[(
Y 0j,t − y0−j,t′W
)2]
is uniformly continuous on W. Therefore, from corollary 2.2 of
Newey (1991), we have that Q˜K converges uniformly in probability to E
[(
Y 0j,t − y0−j,t′W
)2]
for
any subsequence {tk}k∈N.
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B Model with time-invariant covariates
In Section 3 we provide evidence that specification 1 (pre-treatment outcome mean as eco-
nomic predictor) fails to take into account the time-series dynamics of the data, which implies that
the SC estimator using this specification does not converge to the SC estimators using the other
specifications. As a consequence, the possibilities for specification searching do not vanish even
when the number of pre-treatment periods is large. However, in most applications that use the
pre-treatment outcome mean as economic predictor, other time-invariant covariates are also con-
sidered as economic predictors. Here we consider an alternative MC simulation where we include
time-invariant covariates, and we show that the same pattern observed in Section 3 can arise even
when we consider specifications that also include time-invariant covariates as economic predictors.
The alternative DGP is given by:
Y 0j,t = δt + λ
k
t + θtZi + jt (19)
where Zi = 1 for i = 1, ..., 10 and Zi = 0 for i = 11, ..., 20. As in our DGP from Section 3, we
consider K = 10.41 We consider that λkt is normally distributed following an AR(1) process with
0.5 serial correlation parameter, δt ∼ N(0, 1), j,t ∼ N(0, 0.1), and θt ∼ N(0, 1). We consider the
same six specifications as in Section 3, except that we also include Zi as economic predictor.
In column 1 of Table A.8 we present the proportion of misallocated weights for specification
1. Although specification 1’s misallocation of weights is slightly less intense than in the DGP
of the main text, it still misallocates significantly more weight relative to other specifications,
and, importantly, the misallocation of weights remains relatively constant when T0 increases.
42 In
column 2 of Table A.8 we show that our measure of variability of weights also remain constant with
T0, which implies that there is still substantial differences in the SC estimators when we consider
different specifications, even when T0 is large. Given that specification 1 remains very different
from the other specification even with large T0, the possibilities for specification searching remain
high for large T0, as presented in columns 3 and 4 of Table A.8. This is similar to our findings in
Section 3. The intuition is that including Zi as an economic predictor helps prevent that the SC
41Therefore, units 1 and 2 follow the trend λ1t , units 3 and 4 follow the trend λ
2
t , and so on.
42The misallocation for the other specifications is similar to the stationary model considered in Section 3. Results
available upon request.
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estimator will allocate positive weights to units i = 11, ..., 20. However, this specification still fails
to capture the time-series dynamics when allocating weights among units i = 2, ..., 10.
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C Appendix Tables
Table A.1: Specification searching - Alternative Models
Model (8) with j,t ∼ N(0, 1) Model (8) with K = 2
5% test 10% test 5% test 10% test
(1) (2) (3) (4)
T0 = 12 0.121 0.218 0.124 0.225
(0.004) (0.006) (0.005) (0.006)
T0 = 32 0.122 0.211 0.130 0.229
(0.004) (0.006) (0.005) (0.006)
T0 = 100 0.113 0.208 0.118 0.217
(0.004) (0.006) (0.005) (0.006)
T0 = 400 0.100 0.187 0.113 0.202
(0.004) (0.006) (0.005) (0.006)
Note: Rejection rates are estimated based on 5,000 observations and on six specifi-
cations — (1) the mean of all pre-treatment outcome values, (2) all pre-treatment
outcome values, (3) the first half of the pre-treatment outcome values, (4) the first
three quarters of the pre-treatment outcome values, (5) odd pre-treatment outcome
values, and (6) even pre-treatment outcome values. z% test indicates that the nom-
inal size of the analyzed test is z% and T0 is the number of pre-treatment periods.
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Table A.2: Probability of good pre-treatment fit - Alternative Models
Model (8) with j,t ∼ N(0, 1) Model (8) with K = 2
R˜2 > 0.80 R˜2 > 0.95 R˜2 > 0.80 R˜2 > 0.95
(1) (2) (3) (4)
Panel A: At least one specification with good fit
T0 = 12 0.234 0.005 0.991 0.671
(0.003) (0.001) (0.001) (0.007)
T0 = 32 0.008 0.000 1.000 0.642
(0.003) (0.001) (0.001) (0.007)
T0 = 100 0.000 0.000 1.000 0.493
(0.003) (0.001) (0.001) (0.007)
T0 = 400 0.000 0.000 1.000 0.349
(0.003) (0.001) (0.001) (0.007)
Panel B: # of specifications with good fit
T0 = 12 0.615 0.008 5.606 2.764
(0.010) (0.001) (0.008) (0.031)
T0 = 32 0.018 0.000 5.794 2.636
(0.010) (0.001) (0.008) (0.031)
T0 = 100 0.000 0.000 5.823 1.801
(0.010) (0.001) (0.008) (0.031)
T0 = 400 0.000 0.000 5.801 1.322
(0.010) (0.001) (0.008) (0.031)
Panel C: Specification 1 has a good fit
T0 = 12 0.003 0 0.732 0.098
(0.000) - (0.006) (0.003)
T0 = 32 0.000 0 0.796 0.048
(0.000) - (0.006) (0.003)
T0 = 100 0.000 0 0.823 0.002
(0.000) - (0.006) (0.003)
T0 = 400 0.000 0 0.801 0.000
(0.000) - (0.006) (0.003)
Note: Descriptive statistics are estimated based on 5,000 observations and on the six
specifications defined in Section 3. T0 is the number of pre-treatment periods. Our
measure of goodness of fit is defined by equation (10). We consider two definitions
of good fit; R˜2 > 0.80 and R˜2 > 0.95.
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Table A.3: Specification searching conditional on a good pre-treatment fit - Alternative
Models
Model (8) with j,t ∼ N(0, 1) Model (8) with K = 2
5% test 10% test 5% test 10% test
(1) (2) (3) (4)
Panel A: R˜2 > 0.80
T0 = 12 0.235 0.379 0.122 0.222
(0.012) (0.014) (0.005) (0.006)
T0 = 32 0.286 0.524 0.125 0.222
(0.066) (0.075) (0.005) (0.006)
T0 = 100 - - 0.113 0.210
- - (0.005) (0.006)
T0 = 400 - - 0.109 0.194
- - (0.005) (0.006)
Panel B: R˜2 > 0.95
T0 = 12 0.808 0.808 0.144 0.256
(0.079) (0.079) (0.006) (0.007)
T0 = 32 - - 0.135 0.229
- - (0.006) (0.007)
T0 = 100 - - 0.103 0.190
- - (0.007) (0.008)
T0 = 400 - - 0.087 0.152
- - (0.008) (0.01)
Note: Rejection rates are estimated based on 5,000 observations and on six specifi-
cations — (1) the mean of all pre-treatment outcome values, (2) all pre-treatment
outcome values, (3) the first half of the pre-treatment outcome values, (4) the first
three quarters of the pre-treatment outcome values, (5) odd pre-treatment outcome
values, and (6) even pre-treatment outcome values. z% test indicates that the nomi-
nal size of the analyzed test is z% and T0 is the number of pre-treatment periods. Our
measure of goodness of fit is defined by equation (10). We consider two definitions
of good fit; R˜2 > 0.80 and R˜2 > 0.95.
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Table A.4: Variability and Misallocation of weights - Alternative Models
Misallocation of weights in specification: Variability of weights
1 2 3 4 5 6 All Exclude 1
(1) (2) (3) (4) (5) (6) (7) (8)
Panel A: Model (8) with j,t ∼ N(0, 1)
T0 = 12 0.883 0.703 0.734 0.748 0.719 0.725 0.677 0.554
(0.003) (0.003) (0.004) (0.004) (0.004) (0.004) (0.003) (0.003)
T0 = 32 0.872 0.576 0.571 0.618 0.564 0.570 0.631 0.43
(0.004) (0.002) (0.003) (0.004) (0.003) (0.003) (0.002) (0.002)
T0 = 100 0.878 0.508 0.480 0.531 0.477 0.479 0.605 0.295
(0.003) (0.001) (0.002) (0.002) (0.002) (0.002) (0.002) (0.001)
T0 = 400 0.877 0.472 0.461 0.480 0.462 0.459 0.574 0.170
(0.003) (0.001) (0.001) (0.001) (0.001) (0.001) (0.002) (0.001)
Panel B: Model (8) with K = 2
T0 = 12 0.207 0.044 0.049 0.06 0.048 0.048 0.737 0.586
(0.003) (0.001) (0.001) (0.001) (0.001) (0.001) (0.002) (0.003)
T0 = 32 0.219 0.027 0.029 0.041 0.028 0.029 0.673 0.497
(0.003) (0.000) (0.001) (0.001) (0.001) (0.001) (0.002) (0.002)
T0 = 100 0.204 0.016 0.018 0.025 0.018 0.018 0.612 0.372
(0.003) (0.000) (0.000) (0.001) (0.000) (0.000) (0.003) (0.001)
T0 = 400 0.219 0.008 0.010 0.013 0.010 0.010 0.540 0.217
(0.003) (0.000) (0.000) (0.000) (0.000) (0.000) (0.003) (0.001)
Note: The average of misallocated weights is based on 5,000 observations. The reasoning behind this variable is
the following: since, in our DGP, we divide units into groups whose trends are parallel only when compared to
units in the same group, the sum of the weights allocated to the units in the other groups is a measure of the
relevance given by the synthetic control method to units whose true potential outcome follows a different trajectory
than the one followed by the unit chosen to be the treated one. The average of variability of weights is based
on 5,000 observations and captures the average maximum difference of allocated weights across specifications.
Specification s is one of the specifications used to compute the synthetic control unit: (1) the mean of all pre-
treatment outcome values, (2) all pre-treatment outcome values, (3) the first half of the pre-treatment outcome
values, (4) the first three quarters of the pre-treatment outcome values, (5) odd pre-treatment outcome values,
and (6) even pre-treatment outcome values. T0 is the number of pre-treatment periods.
57
Table A.5: Specification searching - Excluding specification 1 - Alternative Models
Model (8) with j,t ∼ N(0, 1) Model (8) with K = 2
5% test 10% test 5% test 10% test
(1) (2) (3) (4)
Panel A: Unconditional
T0 = 12 0.102 0.186 0.098 0.186
(0.004) (0.005) (0.004) (0.005)
T0 = 32 0.106 0.184 0.104 0.186
(0.004) (0.005) (0.004) (0.005)
T0 = 100 0.092 0.172 0.09 0.172
(0.004) (0.005) (0.004) (0.005)
T0 = 400 0.079 0.148 0.081 0.148
(0.004) (0.005) (0.004) (0.005)
Panel B: Conditional on R˜2 > 0.80
T0 = 12 0.234 0.377 0.099 0.187
(0.012) (0.014) (0.004) (0.005)
T0 = 32 0.286 0.524 0.104 0.186
(0.066) (0.075) (0.004) (0.005)
T0 = 100 - - 0.09 0.172
- - (0.004) (0.005)
T0 = 400 - - 0.081 0.148
- - (0.004) (0.005)
Panel C: Conditional on R˜2 > 0.95
T0 = 12 0.808 0.808 0.133 0.243
(0.079) (0.079) (0.006) (0.007)
T0 = 32 - - 0.13 0.223
- - (0.006) (0.007)
T0 = 100 - - 0.103 0.190
- - (0.006) (0.008)
T0 = 400 - - 0.087 0.152
- - (0.008) (0.010)
Note: Rejection rates are estimated based on 5,000 observations and on specifications
(2)-(6), defined in Section 3. z% test indicates that the nominal size of the analyzed
test is z% and T0 is the number of pre-treatment periods.Our measure of goodness
of fit is defined by equation (10). We consider two definitions of good fit; R˜2 > 0.80
and R˜2 > 0.95.
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Table A.6: Specification searching - Excluding specification 2
Stationary Model Non-stationary Model
5% test 10% test 5% test 10% test
(1) (2) (3) (4)
Panel A: Unconditional
T0 = 12 0.125 0.222 0.122 0.218
(0.005) (0.006) (0.005) (0.006)
T0 = 32 0.126 0.231 0.135 0.239
(0.005) (0.006) (0.005) (0.006)
T0 = 100 0.121 0.220 0.128 0.233
(0.005) (0.006) (0.005) (0.006)
T0 = 400 0.114 0.211 0.117 0.213
(0.005) (0.006) (0.005) (0.006)
Panel B: Conditional on R˜2 > 0.80
T0 = 12 0.103 0.185 0.109 0.190
(0.004) (0.005) (0.005) (0.006)
T0 = 32 0.098 0.178 0.117 0.203
(0.004) (0.005) (0.005) (0.006)
T0 = 100 0.089 0.154 0.122 0.219
(0.004) (0.005) (0.005) (0.006)
T0 = 400 0.079 0.142 0.117 0.213
(0.004) (0.005) (0.005) (0.006)
Panel C: Conditional on R˜2 > 0.95
T0 = 12 0.208 0.336 0.121 0.210
(0.012) (0.014) (0.006) (0.007)
T0 = 32 0.188 0.328 0.110 0.189
(0.020) (0.024) (0.005) (0.006)
T0 = 100 0.286 0.429 0.101 0.176
(0.152) (0.178) (0.004) (0.006)
T0 = 400 - - 0.106 0.189
- - (0.004) (0.006)
Note: Rejection rates are estimated based on 5,000 observations and on
specifications (1) and (3)-(6), defined on Section 3. z% test indicates
that the nominal size of the analyzed test is z% and T0 is the number
of pre-treatment periods. Our measure of goodness of fit is defined by
equation (10). We consider two definitions of good fit; R˜2 > 0.80 and
R˜2 > 0.95.
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Table A.7: Specification searching excluding specification 2 - CPS simulations
Log wages Employment
Women Men Women Men
5% test 10% test 5% test 10% test 5% test 10% test 5% test 10% test
(1) (2) (3) (4) (5) (6) (7) (8)
Panel A: Unconditional
T0 = 12 0.110*** 0.198*** 0.106*** 0.184*** 0.119*** 0.205*** 0.110*** 0.199***
(0.012) (0.018) (0.011) (0.016) (0.011) (0.016) (0.013) (0.017)
T0 = 32 0.101** 0.183** 0.096* 0.173* 0.092 0.166* 0.099** 0.190**
(0.025) (0.035) (0.026) (0.037) (0.030) (0.039) (0.023) (0.035)
Panel B: Conditional on R˜2 > 0.80
T0 = 12 0.120*** 0.213*** 0.116*** 0.198*** 0.201*** 0.329*** 0.256*** 0.407***
(0.012) (0.018) (0.012) (0.016) (0.023) (0.025) (0.027) (0.028)
T0 = 32 0.103** 0.186** 0.098* 0.176** 0.126* 0.210** 0.151 0.246
(0.026) (0.036) (0.027) (0.038) (0.042) (0.054) (0.082) (0.109)
Panel C: Conditional on R˜2 > 0.95
T0 = 12 0.163*** 0.274*** 0.173*** 0.283*** 0.431*** 0.528*** 0.409*** 0.545***
(0.015) (0.022) (0.016) (0.021) (0.070) (0.059) (0.066) (0.058)
T0 = 32 0.105** 0.188** 0.094* 0.176** 0.188*** 0.375*** - -
(0.027) (0.037) (0.025) (0.037) (0.043) (0.056) - -
Note: Rejection rates are estimated based on five specifications — (1) the mean of all pre-treatment outcome values, (2) the
first half of the pre-treatment outcome values, (3) the first three quarters of the pre-treatment outcome values, (4) odd pre-
treatment outcome values, and (5) even pre-treatment outcome values — and on 5,000 observations for each outcome variable
(employment and log wages), for each sample (men and women) and number of pre-treatment periods (T0 ∈ {12, 32}). z% test
indicates that the nominal size of the analyzed test is z%. Our measure of goodness of fit is defined by equation (10). We
consider two definitions of good fit; R˜2 > 0.80 and R˜2 > 0.95. * means that we reject at 10% the null that the probability of
rejecting at least one specification at z% is equal to z%. ** means that we reject at 5%, while *** means that we reject at 1%.
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Table A.8: Model with time-invariant covariates
Misallocation Variability Specification Searching
of Weights of Weights 5% test 10% test
(1) (2) (3) (4)
T0 = 12 0.624 0.611 0.126 0.230
(0.005) (0.004) (0.005) (0.006)
T0 = 32 0.615 0.599 0.123 0.224
(0.005) (0.004) (0.005) (0.006)
T0 = 100 0.613 0.593 0.121 0.212
(0.005) (0.005) (0.005) (0.006)
T0 = 400 0.609 0.578 0.108 0.197
(0.005) (0.005) (0.005) (0.006)
Note: This table presents results based on 5,000 observations of the MC simulations
described in Appendix B. Column 1 presents the misallocation of weights for spec-
ification 1 (pre-treatment outcome mean and Zi as economic predictors). Column
2 presents the variability of weights considering all six specifications including Zi as
economic predictor. Columns (3) and (4) present the probability of rejecting the null
in at least one specification at, respectively, 5% and 10% significance level.
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